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Introduction
Evidence based medicine                                                                                                     
The practice of modern medicine should be based on evidence. Yearly researchers deliver new 
publications that increase insight in current medicine and often urge to a substantial change 
in medical practice. The rate at which researchers provide new insights and evidence into 
medicine is staggering. During the year 2004 alone, 54 576 new articles have been published 
just in the domain of cardiovascular disease (CVD)1. Although systematic reviews provide 
evidence to help physician making decisions about health care2, staying up to date with all the 
new evidence is hardly feasible for a busy physician, resulting in delays in implementing new 
knowledge into practice. This knowledge gap might lead to suboptimal care and unnecessary 
health care expenditure3-5. To assist practitioners in keeping up to date and dealing with 
specifi c clinical conditions, various organisations develop guidelines. Guidelines condense the 
available evidence and translate that evidence to concrete recommendations for action – these 
guidelines could provide needed support to implement best practice according to the latest 
evidence6, 7.
The Dutch College of General Practitioners’ guidelines    
Guidelines are defi ned as “systematically developed statements to assist practitioner and 
patient decisions about appropriate healthcare for specifi c clinical circumstances”8. In the 
Netherlands, the Dutch College of General Practitioners (DCGP) develops evidence based 
guidelines to assist general practitioners in dealing with specifi c clinical conditions in a 
primary care setting, including recommendations for CVD risk factor management. A number 
of studies have shown that the availability of guidelines does not necessarily lead to the use 
of these guidelines by physicians. Even when authoritative guidelines are available, changing 
the behaviour of physicians has proved to be diffi  cult6, 7. For example, adherence to the DCGP 
cholesterol guideline in primary practice is low, mainly due to the complexity of the guideline 
and interruption of the workfl ow process of the general practitioner9. These issues are by no 
means limited to only cholesterol guidelines; other investigators also report that barriers to 
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implement guidelines into practice include complexity of the guideline algorithms, diffi  culties 
in changing practice routines, the amount of time needed to and diffi  culty in remembering 
preventive tasks10-12.  Various authors have shown that integrating a clinical decision support 
system into the electronic health record of a physician is an eff ective strategy to introduce 
guidelines into daily practice13, 14.
Clinical decision support systems       
Clinical decision support systems (CDSSs) are information systems that aim to optimize physi-
cians’ clinical decision making. Several studies have shown that CDSS can facilitate change in 
physician behaviour15, 16. Guidelines frequently simplify complicated algorithms; a complex risk 
function, for example, is reduced to a graphical table that can readily be understood and used 
by the reader. Simplifying complex algorithms into graphical tables, however, might lead to a 
limited performance of the underlying data calculation models. CDSS obviate the need for this 
simplifi cation as these systems can easily calculate the complex algorithms. Therefore, where 
previously users were required to make interpolations for complex treatment decisions, CDSS 
can now assist users in coming to evidence based decisions. To get to the point of eff ective 
CDSS, however, is not as simple as constructing an algorithm. 
As the complexity of a CDSS increases so, does the need for relevant patient data that 
the system uses to guide practice. This data must have meaning for the system. For example, 
the letters “CHOL” recorded in a system might clearly mean Cholesterol to a human user. To 
a computer, however, “CHOL” means nothing until some form of structure and meaning has 
been given to these letters. This is achieved by structuring and coding of data. Coded data 
relies on widely used coding schemes to record data. In The Netherlands general practitioners 
generally use the International Classifi cation for Primary Care (ICPC) for coding diagnoses and 
the Anatomical Therapeutical Classifi cation (ATC)17 for coding medication. Structuring data is 
achieved by organizing data in a way that it allows an automatic interpretation. For example 
using the letters “CHOL” in the previous example means nothing until the system can translate 
it into a meaning: i.e. “CHOL” means cholesterol. A system that is integrated with an electronic 
patient record, therefore, is highly dependant on the structure and quality of data that is 
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captured by a user. 
General practice and the state of CDSS in the Netherlands   
General practitioners (GPs) function as gatekeepers in the Dutch healthcare system. Most 
patients will fi rst visit a GP with health related problem. In addition, more than 95% of GPs in 
the Netherlands have adopted an electronic health record into daily care entering patient data 
during patient encounters18, 19. This leads to opportunities to study various CDSS in primary 
care. Various success factors for the implementation of a CDSS into daily practice have been 
described. These factors include providing support as part of the clinician’s workfl ow, providing 
decisions at the point of care, providing recommendations rather than just assessments, and 
providing computerized decision support16, 20. 
Apart from taking into account success factors, the designer of a CDSS has the choice 
between diff erent methods of introducing CDSS in daily practice. Two methods of introducing 
CDSS in daily practice have been studied: on-demand mode and alerting mode.  Using the fi rst 
method, the on-demand mode (also referred to as order entry mode), the user decides when 
decision support is needed and then activates the CDSS. In a randomized trial Van Wijk et al, 
using the on-demand method, assessed the impact on the volume of test ordering, of the deci-
sion support system BloodLink, on the volume of test ordering, and determined the compliance 
of Dutch general practitioners to the recommendations for test ordering as defi ned in the 
guidelines of the Dutch College of General Practitioners14. Through the eff ect of BloodLink on 
the test ordering behaviour of the GPs the authors demonstrated the eff ective introduction of 
guidelines into daily practice using an on-demand  CDSS: a physician had to activate the deci-
sion support system to get specifi c support during a relevant patient encounter. This method, 
therefore, implicitly requires the physician’s awareness of the need for specifi c support in a 
specifi c clinical situation. For example if a patient presents with minor respiratory complaints 
and simultaneously is known with various cardiovascular risk factors the physician needs to 
be aware of the encounter’s diff erent aspects. Firstly the patient requires treatment for his or 
her respiratory complaints. Secondly, the patient’s visit provides an opportunity for possible 
primary prevention given the patient’s cardiovascular risk factors.
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In a second method of implementing CDSS, the so called alerting or critiquing mode, the 
user is alerted when advice is available on a patient. The Asthmacritic study used alerting and 
critiquing, to implement guidelines into primary care21. In this study a CDSS was integrated into 
the EHR, providing a physician with comments on a patient’s status according to the DGCP 
guidelines’ recommendations on asthma and chronic obstructive pulmonary disease. Providing 
alerts, however, demands a tight integration with the host EHR - the systems can alert a physi-
cian that an extra action needs to be taken during a patient encounter only if suffi  cient data are 
available. For example, taking the previously mentioned example of the patient with respiratory 
complaints with cardiovascular risk factors; the CDSS based on data available in the electronic 
record alert the physician that prevention is necessary. 
Both methods of providing decision support have advantages and disadvantages. On-
demand or Order entry systems, can be argued, are less obtrusive, less complicated due the 
lower integration level into the EHR, and only provide support when activated. However, these 
systems can lead to lost opportunities for care. The main advantage of alerting systems is the 
ability to make users aware of the need for actions. However, the tight integration into the EHR 
and possible inopportune alerting places extra demands on developers.
Although it is known that both systems are eff ective in providing decision support in 
various settings16, no direct comparison of the two methods has been made. We constructed 
CholGate, a CDSS to aid in the management of primary and secondary prevention of CVD to 
study these diff erent strategies.
Outline of thesis         
To compare the methods of providing decision support we needed a domain where there 
would be frequent diffi  cult decision making. It is known that cardiovascular disease (CVD) is 
the leading cause of mortality in industrialized countries22. Coronary heart disease and stroke 
are the principle components of CVD. Risk factors for developing CVD include smoking, male 
gender, diabetes mellitus, hypertension, haemostatic factors, family history of CVD, age, and 
abnormal blood lipids23. Evidence exists that managing CVD risk factors in primary care plays 
an important role in decreasing the morbidity and mortality due to cardiovascular disease24-26. 
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Additionally, drug treatment for elevated cholesterol among patients with an increased risk for 
cardiovascular disease leads to a decreased morbidity and mortality27, 28. The management of 
CVD risk factors is generally referred to as primary and secondary prevention of CVD. Primary 
prevention aims to lower the incidence of the event, in other words, prevent the occurrence of 
CVD. Secondary prevention aims at reducing more and severe occurrences of CVD after the on-
set of initial CVD. The general practitioner is in a large part responsible for eff ective primary and 
secondary prevention of CVD. However, the treatment decisions in the current DCGP guidelines 
on primary and secondary prevention are complex, and spread over diff erent guidelines29-34. 
This thesis lists the research that was performed in order to compare the two methodologies of 
providing decision support.
In Chapter 2 we address the question: “Do the practice guidelines of the Dutch College of 
General Practitioners allow the identifi cation of clear and unambiguous recommendations with 
respect to the management of CVD risk factors in primary care?” 
In Chapter 3 we focus on: “To what extent do general practitioners monitor the four conven-
tional risk factors, and the associated measurements for cardiovascular risk factors in relation to 
the time of fi rst clinical presence of CVD?”
In Chapter 4 we ask ourselves: “To what extent do Dutch general practitioners adhere to the 
recommendations for treatment and monitoring hypertension and hypercholesterolemia as 
defi ned in the guidelines of the Dutch College of General Practitioners?”
Evidence-based medicine requires that guidelines be revised in the light of the available ran-
domized clinical trials35. New trials that fi rst appear in medical journals are read by physicians, 
and may subsequently result in revision of guidelines. Adoption of recent knowledge into daily 
practice could therefore precede dissemination of revised guidelines. In Chapter 5, we analyze 
statin prescription by Dutch GP’s and compare the risk of cardiovascular and cerebrovascular 
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events between atorvastatin users and other statin users in daily general practice.
In Chapter 6 we describe the system design of CholGate, a system to improve both primary 
and secondary prevention of CVD. Taking advantage of the use of electronic health records 
(EHR) by Dutch general practitioners, CholGate is integrated within the EHR to provide decision 
support in the clinician’s workfl ow. Firstly, we discuss the underlying knowledge base of the 
system. Secondly, we highlight issues in gathering relevant patient data to identify patients at 
risk. Thirdly, we discuss the system’s user interface and workfl ow impact, and, fi nally, we focus 
on special considerations in implementing the system.
In Chapter 7 we address the following question by means of a randomized controlled trail: 
“Does providing alerts give better result in primary care than on-demand decision support?”
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Abstract
Objective: To identify the possible inconsistency of statements among the practice guidelines 
of the Dutch College of General Practitioners (DCGP) with respect to the management of risk 
factors for cardiovascular disease (CVD).
Methods: Cross sectional analysis of all electronically available DCGP practice guidelines 
dealing with CVD risk factor management for statement inconsistencies and reference 
inconsistencies.
Results: Six DCGP out of 74 electronically available guidelines had either CVD or CVD risk 
factors as subject of the guideline. Eight statement inconsistencies were found and for each 
statement inconsistency a reference inconsistency was present.
Conclusions: Given that inconsistencies were found, we recommend that organizations that 
maintain a set of guidelines update the guidelines using a cross sectional analysis of guidelines. 
Inconsistencies between guidelines might lead to physicians being unintentionally non-
compliant with guideline recommendations.
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Introduction
Cardiovascular disease (CVD) is the leading cause of mortality in industrialized countries. Risk 
factors for developing CVD include smoking, male gender, diabetes mellitus, hypertension, 
haemostatic factors, family history of CVD, age, and abnormal blood lipids1. Evidence exists that 
managing CVD risk factors in primary care plays an important role in decreasing the morbidity 
and mortality due to cardiovascular disease2, 3. However, getting evidence into practice is one 
of the major challenges of modern medicine. To deal with the rapidly expanding amount 
of medical knowledge, guidelines are viewed increasingly as a mechanism for distributing 
knowledge to practitioners4, 5. Guidelines are defi ned as “systematically developed statements 
to assist practitioner and patient decisions about appropriate healthcare for specifi c clinical 
circumstances”6. In the Netherlands, the Dutch College of General Practitioners (DCGP) devel-
ops evidence based guidelines to assist general practitioners in dealing with specifi c clinical 
conditions in a primary care setting, including recommendations for CVD risk factor manage-
ment. All guidelines are published both in “Huisarts en Wetenschap”, the scientifi c journal of the 
DCGP, and on the internet7. 
A number of studies have shown that the availability of guidelines does not necessarily 
lead to the use of these guidelines by physicians. Even when authoritative guidelines are avail-
able, changing the behaviour of physicians has proved to be diffi  cult8, 9. For example, adherence 
to the DCGP cholesterol guideline in primary practice is low, mainly due to the complexity of 
the guideline and interruption of the workfl ow process of the general practitioner10. Several 
studies using diff erent strategies of guideline implementation have shown varying degrees of 
success9, 11-13. A number of studies showed an eff ective strategy for guideline implementation is 
integrating guideline based decision support systems (DSS), into the electronic medical record 
(EMR)14-16. The objective of the systems is to help the physicians in making guideline based 
healthcare decisions at the point of care.
In order to implement a guideline in a DSS, developers need to formalize the statements 
of the guideline. However, with respect to the management of chronic diseases, more than 
one guideline can be applicable. In addition patients may have more than one disease. If a 
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statement in one guideline is inconsistent with a statement in another guideline the developer 
is confronted with ambiguous recommendations. It means that the developer will not be able 
to formalize the guidelines appropriately. Therefore, to determine whether guidelines provide a 
consistent base for the development of a DSS, developers have to perform a careful analysis on 
consistency of guidelines17.
The objective of this study is to identify the possible inconsistency of statements among 
the practice guidelines of the DCGP with respect to the management of CVD risk factors. We 
want to determine whether these guidelines provide a consistent base for the development of 
a decision support system for the management of CVD risk factors. 
Methods
We defi ne statements as actions suggested in guidelines to be performed by the physician in 
the clinical management process.
To identify possible inconsistencies among guidelines with respect to the management of 
CVD, we analyzed all clinical practice guidelines of the DCGP available on 1 September 20027. 
Guidelines with CVD or diabetes mellitus, blood lipids, hypertension, smoking, and haemostatic 
factors as the subject of the guideline were selected for analysis.
All guidelines adhered to a common structure. This structure consisted of 3 sections with 
subsections: Introduction and background, diagnosis and evaluation, and treatment. Apart 
from the fi rst section “Introduction and Background”, the guideline sections corresponded to 
the subjective, objective, assessment, and plan (SOAP) methodology for problem orientated 
patient recording18, 19. The second section, “Diagnosis and evaluation”, included screening and 
history taking, physical examination, special investigations, and evaluation which corresponded 
to the subjective, objective, and assessment components of the SOAP methodology. The third 
section, “Treatment”, corresponded to the plan component of the SOAP methodology (Figure 
1).
To identify inconsistencies among the selected guidelines we compared statements that 
contained similar actions. To avoid mismatching of statements among the guidelines, we veri-
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fi ed that statements were comparable with respect to the distinctive components of the clinical 
management process. For example, a screening test in one guideline cannot be compared 
to a therapy eff ectiveness test in another guideline. That is, we identifi ed whether statements 
applied to the same clinical scenario in dealing with a patient in order to avoid mismatching 
statements with diff erent clinical endpoints. A statement inconsistency refers to the situation in 
which a statement in one guideline recommends a certain action in a specifi c scenario, whereas 
the comparable statement in another guideline does not recommend the same action for that 
scenario or recommend a diff erent action to the same scenario. To gain insight into whether 
guideline authors compared statements in related guidelines, we determined for each state-
ment inconsistency whether cross references were present between the guidelines. 
Results
The DCGP published 74 guidelines up to 1 September 2002. Six guidelines of the 74 electroni-
cally available guidelines satisfi ed the selection criteria of CVD or diabetes mellitus, blood lipids, 
and hypertension as subject of the guideline. The angina pectoris20, peripheral arterial disease21, 
and transient ischaemic attack (TIA)22 guidelines satisfi ed the selection criterion of CVD as 
subject of the guideline. For blood lipids, diabetes mellitus and hypertension23-25 separate 
guidelines existed. No guidelines dealt with smoking, age or haemostatic factors as subject of 
the guideline.
In the six identifi ed guidelines, we found a total of eight statement inconsistencies: two in 
the subjective component, two in the objective component and four in the plan component. 
The diabetes mellitus and cholesterol guidelines showed the highest number of statement 
inconsistencies. For each of the statement inconsistencies, a reference inconsistency was 
present. Table 1 shows all statement inconsistencies.
Discussion
The objective of this study was to identify the possible inconsistency of statements among 
the practice guidelines of the DCGP with respect to the management of CVD risk factors. We 
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wanted to determine whether these guidelines provide a consistent base for the development 
of a decision support system for the management of cardiovascular disease risk factors.
Most statements in the selected guidelines were consistent. However, we identifi ed eight 
statement inconsistencies. Formalization of guidelines requires consistency of guideline state-
ments. When viewing the guidelines as an integral part of the overall risk management of CVD 
the signifi cance of inconsistencies becomes apparent. For example, in our analysis we found 
that the cholesterol guideline stated explicitly that triglyceride testing should not be done, 
even in the case of patients suff ering from diabetes mellitus. However, the diabetes mellitus 
guideline states that a diabetic should have a triglyceride value determined yearly. Guidelines 
are defi ned as “systematically developed statements to assist practitioner and patient decisions 
about appropriate healthcare for specifi c clinical circumstances”6. Our focus was to fi nd directly 
contradictory statements that would be irreconcilable in implementing a DSS. The clinical 
relevance of the contradictions remains open for debate. For example, one guideline (diabetes) 
recommends treating diabetic patients with cholesterol abnormalities with statins, and only 
after treatment is not successful the GP should refer the patient. Another guideline (cholesterol) 
recommends for the same population immediate referral to a specialist. From the patient 
outcome perspective, the diff erence might not be large. From designing a DSS, however, these 
constitute diff erent recommendations; if these statements between guidelines are inconsistent, 
appropriate assistance through a DSS will not be possible.
If authoritative organisations develop guidelines, clinicians will rely on those guidelines, 
and may consider consistency to be implicit. Furthermore, if guideline issuing organisations 
aim to improve compliance to guidelines, consistency among the guidelines of that same 
organisation is a prerequisite. Even if general practitioners intend to adhere to guidelines, they 
will not succeed to adhering to more than one guideline simultaneously if a patient suff ers from 
more than one disease and the guidelines are inconsistent. This urges the guideline developing 
organisations to carefully review previously released guidelines for statement inconsistencies 
between guidelines during the process of updating guidelines or drafting new guidelines. 
Given that inconsistencies were found, we recommend that organizations that maintain a set of 
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guidelines provide physicians with a list of known inconsistencies among those guidelines. 
A few mechanisms might cause inconsistencies among the DCGP guidelines. Firstly, 
although the available scientifi c evidence plays an important role, the DCGP acknowledges 
that the guidelines are, to a varying degree, dependent on subjective opinions of individuals 
involved in the creation of that guideline26. Each guideline is based on arguments of the 
individual members of the taskforce and subsequent reviewers. However, for each guideline dif-
ferent general practitioners participate in the taskforce. The process of developing guidelines, 
therefore, does not guarantee consistency.
Secondly, the timeframe in which guidelines are developed and revised might be another 
cause of inconsistencies. For example the hypertension and peripheral arterial disease guide-
lines that the cholesterol guideline refers to were revised after the revision of the cholesterol 
guideline.
Thirdly, as new evidence becomes available, the DCGP issues new guidelines and revises 
existing guidelines. Therefore, corresponding statements in diff erent guidelines can be based 
on diff erent evidence. This is an inherent limitation to the current paper-based guideline 
development and revision process. The fact that for all statement inconsistencies a reference 
inconsistency exists is another example of the limitation of the DCGP paper based guidelines 
development process. Given that guidelines are electronically available, guideline developers 
might hyperlink corresponding statements in recently issued or revised guidelines to state-
ments in previously issued guidelines enabling the updating of existing guidelines with new 
evidence. Linking statements facilitates the review process with respect to inconsistencies in 
related guidelines facilitating the formalization of these guidelines for use in a DSS, and leading 
to consistent cross referencing. 
The fact that all guidelines adhere to a common structure consisting of sections, and being 
translatable to the SOAP methodology could be important for developers of DSS. If physicians 
apply the SOAP methodology entering patient data, decision support based on the cor-
responding section of guidelines could be linked to the distinctive components of the clinical 
management process, enabling the physician to integrate the guideline into the patient’s 
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management process
Currently various groups are working on modelling guidelines to be computer interpret-
able27-29,30. However, none of these groups explicitly require consistency among guidelines. We 
believe that consistency between guidelines is a prerequisite in the development of computer 
interpretable guidelines. Adherence to guidelines does not solely rely on the implementation 
strategy chosen for the guideline, but on consistency of the guidelines themselves as well. 
Recently Shiff man et al published a checklist of 18 points for guidelines structure31. However, 
this checklist does not mention the cross consistency in statements and the cross consistency 
in referencing of related guidelines; issues that in our opinion should be added to the checklist 
for guideline structure. Modelling of guidelines to be computer interpretable should start with 
a careful analysis and updating of guidelines on consistency by guideline developers. This will 
assist the subsequent implementation of several guidelines into DSS by system developers, 
as well as clarifying the management of a single patient with multiple chronic diseases by 
physicians. A cross guideline consistency enables the physician to integrate across relevant 
guidelines into the patient’s management process. Further research is necessary to assess the 
feasibility of this approach.
We believe that the strength in our study lies in the fact that we performed the fi rst cross 
sectional analysis of all CVD risk factor statements in all relevant guidelines issued by the DCGP. 
Our approach might also be applicable on guidelines for managing CVD risk factors developed 
by other organizations.
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Figure 1. The DCGP guideline sections and subsections with the corresponding 
components of the problem orientated patient recording methodology (Subjective, 
Objective, Assessment, and Plan)
Cross sectional analysis of guidelines
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Abstract
Background: Detecting and managing the four major conventional risk factors – smoking, 
hypertension, diabetes mellitus, and hypercholesterolemia is pivotal in the primary and 
secondary prevention of cardiovascular disease (CVD).
Objective: To assess the preventive activities of general practitioners regarding the four 
conventional risk factors, and the associated measurements for cardiovascular risk factors by 
general practitioners in relation to the time of fi rst clinical presence of CVD.
Setting: Large longitudinal general practice research database (IPCI) in the Netherlands from 
September 1999 to August 2003.
Participants and methods: Patients older than 18 with newly diagnosed CVD with at least one 
year of valid history before and after fi rst clinical diagnosis of CVD. Details on conventional risk 
factors and associated measurements for the four cardiovascular risk factors were assessed in 
relation to the fi rst clinical diagnosis of CVD.
Results: In total 157 716 patients met the inclusion criteria. Of the 2594 patients with newly 
diagnosed CVD, at least one of the four investigated risk factors was observed in 76% of females 
and 73% of males. In 40% of cases no risk factor was recorded before the date of fi rst CVD. In 
16% of cases no associated measurements were present before the fi rst CVD diagnosis.
Conclusion: In daily practice general practitioners seem to focus on secondary prevention of 
CVD. Intervention strategies that aim to infl uence general practitioners’ case fi nding behaviour 
should focus on increasing the awareness of physicians in performing risk factor associated 
measurements in patients eligible for primary prevention of CVD. Further research will have to 
show the feasibility and eff ectiveness of such intervention strategies.
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Introduction
In the Netherlands, the Dutch College of General Practice (DCGP) develops evidence-based 
guidelines to assist general practitioners (GPs) in dealing with specifi c clinical conditions, 
including recommendations for preventive activities regarding cardiovascular disease (CVD) risk 
factor management 1-6.  These guidelines correspond to internationally developed guidelines 
on the prevention of atherosclerotic disease7,8.
Recent studies emphasize the value of detection of the so-called four conventional or 
major risk factors for CVD: Smoking, hypertension, diabetes mellitus, and hypercholesterolemia 
9,10. Managing these four risk factors plays an important role in the primary and secondary 
prevention of cardiovascular disease 11,12. All international guidelines on the prevention of 
atherosclerotic disease emphasize the need to manage these four major risk factors 7,8.
However, a number of researchers have argued that although authoritative guidelines 
are available, both primary and secondary prevention of CVD are sub-optimally performed 
13-19. Little is known about GPs’ preventive activities regarding major risk factors and associated 
measurements for cardiovascular risk factors in relation to the fi rst clinical presence of CVD.
In this study we assess the preventive activities of GPs regarding the four conventional risk 
factors and associated measurements for these risk factors in patients eligible for primary or 
secondary prevention of CVD in relation to the time of fi rst clinical presence of CVD. 
Methods
Setting          
We conducted a retrospective cohort study in the Integrated Primary Care Information (IPCI) 
database. IPCI is a longitudinal GP research database, which contains information from com-
puter-based patient records of GPs in The Netherlands. Within The Netherlands, patients are 
registered at single GP and the record for each individual patient contains all medical informa-
tion on that patient 20,21. The database contains information on approximately 500,000 patients.
The computer records contain information on patient demographics, symptoms (free text), 
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diagnoses (using the International Classifi cation for Primary Care (ICPC)), episodes, referrals, 
laboratory values, measurements (e.g. BP, cholesterol levels), drug prescriptions with their 
ICPC-coded indications, and hospitalizations 22,23. Summaries of the hospital discharge letters 
or information from specialists are available in a free text format. To maximize completeness of 
the data, GPs who participate in the IPCI project are not allowed to use paper-based records. 
The system complies with European Union guidelines on the use of medical data for medical 
research and has been proven valid for epidemiological research 24.
Source population and CVD study cohort      
The source population comprised all subjects of 18 years and older, with at least one year of 
valid database history. This means that the patient was registered for at least one year with 
the GP and the GP should participate in the IPCI project for at least one year. All subjects were 
followed from the latest of the following dates: one year of valid history, age 18, or start of the 
study period (September 1999) until death, transferral out of practice, last data draw down or 
end of the study period (August 2003), whichever came fi rst. 
The CVD study cohort comprised all subjects with a fi rst recorded diagnosis of clinical 
atherosclerotic disease, defi ned as  clinical coronary heart disease (angina pectoris, myocardial 
infarction), transient ischaemic attacks (TIA), ischaemic cerebrovascular attacks, and peripheral 
arterial disease 2. Because our study focused on preventive activities of GPs in relation to the 
time of fi rst clinical presence of the predefi ned atherosclerotic disease, we excluded all patients 
with less than one year of follow-up after the fi rst event.
Defi nition of the risk factors hypertension, diabetes mellitus, 
hypercholesterolemia, and smoking, and associated measurements  
We evaluated the so called modifi able conventional or major risk factors for developing 
atherosclerotic disease. The guidelines of the DCGP dealing with primary and secondary 
prevention of CVD focus on smoking, hypertension, diabetes, and hypercholesterolemia as 
modifi able risk factors. These guidelines are familiar to and considered authoritative by Dutch 
GP’s. Because our objective was to assess preventive activities of Dutch GP’s in daily practice 
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we restricted ourselves to these so called four conventional risk factors. The Dutch guidelines 
on prevention of CVD correspond to widely accepted international guidelines on prevention 
of CVD (i.e. National Cholesterol Education Program’s Adult Treatment Panel III guideline, the 
European guidelines on prevention of coronary heart disease, guidelines of the American 
College of Physicians, and guidelines of the American Heart Association/American College of 
Cardiology) 7,8,25,26. 
Patients were considered to suff er from the risk factor hypertension if they had an 
ICPC coded diagnosis of hypertension by the GP or a specialist, or if they were treated with 
antihypertensive drugs (thiazides, beta-blockers, calcium channel blockers, ACE-inhibitors, or 
angiotensin-II antagonists), while excluding prescriptions for angina pectoris or heart failure. 
The risk factor diabetes mellitus was identifi ed by an ICPC coded diagnosis of diabetes by 
the GP or a specialist, or if treatment was present with insulin or oral antidiabetics.
Because the ICPC classifi cation does not distinguish between the various lipid abnormali-
ties, patients were considered to have the risk factor hypercholesterolemia in the presence of a 
total cholesterol value greater than 5 mmol/l (1999 DCGP cholesterol guideline). For all condi-
tions we determined the date of fi rst presence in the record and assumed that these conditions 
were chronic. 
Information on the risk factor smoking was obtained from the medical records and 
information on active smoking as well as non-smoking was considered. 
Associated measurements were measurements used to determine the presence of a risk fac-
tor. For smoking the measurement was a question regarding smoking status. For hypertension 
the associated measurement was the recording of BP value. For diabetes it was the presence of 
a glucose measurement. For hypercholesterolemia it was the presence of a serum cholesterol 
test.
Preventative activities of General Practitioners     
We established whether any patient in our CVD cohort had hypertension, hypercholestero-
lemia, diabetes, or smoked. We calculated prevalences at the end of the observation period. 
Subsequently we assessed whether the diagnosis in the patient record of these risk factors 
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occurred before the fi rst recorded diagnosis of clinical atherosclerotic disease, on the same day 
that clinical atherosclerotic disease was recorded, or after the recording of clinical atheroscle-
rotic disease. 
We established whether any patient in our CVD cohort had a cholesterol measurement, a 
BP measurement, a glucose test, or a noted enquiry on smoking status. We calculated preva-
lences at the end of the observation period. Subsequently we assessed whether the measure-
ments were performed before the fi rst recorded diagnosis of clinical atherosclerotic disease, on 
the same day that clinical atherosclerotic disease was recorded, or after the recording of clinical 
atherosclerotic disease.
Statistical Methods         
Categorical data are presented as percentages, and continuous data are presented as means 
(SDs). Were applicable, frequencies were analyzed using χ2 tests, and continuous variables were 
analyzed by Mann-Whitney U tests. We used SPSS version 11 (SPSS Inc, Chicago, IL) for analyz-
ing data. We considered comparisons signifi cant at P<0.05.
Results
Of the 157 716 patients who met the inclusion criteria in the source population, a fi rst recorded 
diagnosis of clinical atherosclerotic disease occurred in 2594 patients (52.7% male, 47.3% 
female) during the study period. At the end of the observation period of all patients with newly 
diagnosed CVD, 40.7 % had recorded hypertension, 41.7 % had recorded hypercholesterolemia, 
16.5% had diabetes mellitus and 28.2% had been or were smokers. At the end of the observa-
tion period 74.4% of newly diagnosed CVD patients had at least one of the four risk factors. 
Table 1 shows the number of associated measurements for conventional risk factors and risk 
factors by gender.
Table 2 shows when individual risk factors were recorded in relation to the fi rst diagnosis 
of CVD. As shown in table 2, of the 732 patients who smoked, 62% were known to smoke before 
the CVD event (the primary prevention window), 19% were recorded as smokers on the same 
day that CVD was diagnosed, and 19% were recorded as smokers after the fi rst CVD event.
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Table 3 shows the cumulative number of risk factors present per patient related to the time 
of fi rst CVD diagnosis. The total number of risk factors present per patient increased on or after 
the date of fi rst CVD diagnosis, the percentage of patients with no risk factors decreased from 
39.7% to 25.6%.
Table 4 shows the fi rst entry of associated measurements for cardiovascular risk calculation 
related to the time of fi rst CVD diagnosis. Of all new CVD patients, 957 (36.9%) patients had 
a measurement for smoking. When measurements were related to the fi rst diagnosis of CVD, 
61.8% were before the fi rst diagnosis of CVD, 20.2% were on the same day as the diagnosis, and 
18.1% were after the diagnosis.
Table 5 shows the total number of associated measurements for cardiovascular risk factors 
per patient related to the time of fi rst CVD diagnosis. In 15.9% of cases no measurements were 
present before the fi rst CVD diagnosis. The percentage of patients with no associated measure-
ments decreased on or after the date of fi rst CVD diagnosis to 2.4%. Only 18.2% of patients had 
all associated measurements performed after the fi rst diagnosis of CVD.
Discussion
Statement of principal fi ndings       
The aim of this study was to assess the identifi cation of the 4 conventional risk factors, and as-
sociated measurements by GPs in patients eligible for primary or secondary prevention of CVD. 
The prevalence of conventional risk factors in our data set corresponds to previously published 
data on conventional risk factors 9,10. All the 2594 patients in our study were required to have 
at least one year of observation before the fi rst CVD event was diagnosed – time during which 
they were eligible for primary prevention. In approximately 60% of patients the risk factor was 
known before the fi rst diagnosis of CVD, however only a fraction (10%) of patients had all risk 
factor measurements before the fi rst diagnosis of CVD. More than half of patients had one or no 
risk factor measurement before the fi rst diagnosis of CVD. We believe benefi t can be gained for 
patients at risk of CVD by screening for risk factors in an earlier stage.
A comparison of when risk factors were present in relation to the date of CVD diagnosis 
Identifi cation of “Conventional” Risk Factors
39
showed that - if a risk factor was present - diabetes, hypertension, and hypercholesterolemia 
were diagnosed in greater numbers (75-79%) than smoking (62%) before the fi rst recorded 
diagnosis of CVD. Of patients with smoking and hypertension, 19% and 5% respectively had 
the fi rst entry of the risk factor on the date of CVD diagnosis. In 40 % of patients no risk factor 
was present before the fi rst recorded diagnosis of CVD. However, on the day of CVD diagnosis, 
the number of patients without a risk factor decreased by 6%, and by a further 9% after the 
CVD diagnosis. We conclude that GPs tend to complete their screening for risk factors when 
confronted with a new CVD event. In the light of the evidence on reducing the number of CVD 
events by early identifi cation and management of risk factors, much is to be gained in infl uenc-
ing the GPs’ case fi nding behaviour in primary prevention of CVD 27-30.
Only BP measurements were recorded in the majority of new CVD patients. Measurements 
for cholesterol, smoking and glucose were recorded in 50 to 60% of patients. Physicians 
frequently recorded measurements on or after the fi rst recorded diagnosis of CVD. This 
indicates that the confrontation with the CVD event triggered the physician to assess additional 
risk factors. The DCGP guidelines recommend cholesterol, glucose, BP and smoking status 
measurements in all patients with CVD. The fact that only BP measurements were performed in 
most patients with CVD indicates that GPs show moderate compliance with DCGP guidelines’ 
recommendations regarding secondary prevention of CVD. Of all patients, 15.9% had no risk 
factor measurements in their records before the fi rst recorded diagnosis of CVD. This could 
explain why approximately 40% of all the patients who developed CVD, did not have a risk 
factor present before the fi rst diagnosis of CVD. For primary prevention to be successful, case 
fi nding of risk factors by performing associated measurements is a prerequisite.
Strengths and weaknesses of the study       
Our study benefi ts from the fact that it was done in an observational database, refl ecting GPs’ 
actions without any intervention by the researchers. GPs are not forced to adhere to study 
protocols and are free to record what they want. That our study refl ects prevalence found by 
other groups, makes our fi ndings generalizable 9,10. As is noted by other authors, a weakness 
of observational data is that these refl ect what GPs chose to capture in their records 31. This 
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can lead to an underestimate of risk factor identifi cation and measurements in our study. The 
prevalence of smoking shown in our work is an example of the diffi  culties in determining the 
risk status of individuals purely from observational data. The prevalence of smokers in our study 
was less, compared to the known Dutch prevalence 32. This can be partly explained by smokers 
hiding their smoking status from physicians, resulting in a lower than expected smoking 
prevalence observed in general practice 33, and GPs not recording normal values (i.e. “non 
smoker”).
Strengths and weaknesses in relation to other studies, discussing important 
diff erences in results          
Khot et al showed that the four conventional risk factors are related to the development of 
CVD 9. Our data confi rm this in an observational setting. As mentioned before our study might 
underestimate the number of risk factors in CVD (71-75% with at least one risk factor and CVD 
vs. 85-90% in Khot et al). This can partly be explained by the diffi  culty in obtaining complete 
data in an observational setting. In addition, our data indicate that the records of patients 
without CVD but with a risk factor present show few associated measurements for cardiovascu-
lar risk calculation.
We do not know of other studies which looked at the timeframe of risk factor diagnosis 
in relation to the fi rst diagnosis of any clinical atherosclerotic disease, nor any that evaluated 
when the fi rst associated measurements for risk profi le estimation were performed in relation 
to the fi rst CVD diagnosis. One study in similar observational setting looking at risk factor 
management in CVD, found that the management of these risk factors was poor 31. A Dutch 
study showed that in a selected population under-screening and under-treatment of patients 
eligible for primary or secondary prevention of CVD is common 34. The identifi cation of risk 
factors based on abnormal values of associated measurements for cardiovascular risk calcula-
tion, precedes the adequate management of risk factors. Our study shows that the insuffi  cient 
attention to performing associated measurements for cardiovascular risk calculation hampers 
eff ective primary prevention.
With respect to the management of the four conventional risk factors, the Dutch 
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guidelines on prevention of CVD correspond to international guidelines. The main focus of the 
guidelines is the early detection and management of these four modifi able risk factors.
Our defi nition of hypercholesterolemia is a blood cholesterol value greater than 5 
mmol/l. This value is used in the Netherlands to defi ne abnormal high blood cholesterol; in 
the presence of atherosclerotic disease it warrants medical treatment. This diff ers from other 
international guidelines that emphasize LDL cholesterol testing as an important indicator of 
abnormal lipid values. However since all international guidelines emphasize the early detection 
of abnormal blood lipid values, we do not believe that this will make our results less generaliz-
able; we believe that GP’s threshold for early detection is low, irrespective of which blood lipid 
value is used.
In the Netherlands the DCGP guidelines are viewed as authorative. However, having autho-
rative guidelines available does not directly translate into compliance to guidelines. Diff erent 
strategies of guideline implementation have shown varying degrees of success in improving 
compliance 35-38. A number of studies showed an eff ective strategy for guidelines implementa-
tion is integrating guideline based decision support systems (DSS), into the electronic medical 
record (EMR) 39,40. The objective of the systems is to help the practitioners in making guideline 
based healthcare decisions at the point of care, therefore increasing adherence to guidelines, 
and indirectly, favourably infl uencing patient outcomes – the main aim of evidence based 
medicine. The availability of enough relevant data, however, is a prerequisite for any decision 
support system to give proper support.
The majority of GPs in The Netherlands have replaced their traditional paper-based patient 
records with computer-based patient records, the physicians entering patient data themselves 
in the computer during patient encounters 21. The use of electronic patient records creates 
new opportunities for the implementation of decision support systems; integration of decision 
support facilities with electronic patient records provides a natural way to support clinical 
practice 39-42.
Our study shows that concerning CVD management, data regarding risk factors are 
available, but frequently too “late”. The essence of primary prevention is the identifi cation of risk 
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factors by performing associated measurements in patients at risk of atherosclerotic disease 
preceding the event. Giving GP’s the tools to identify patients eligible for primary prevention, 
might invite them to perform associated measurement for cardiovascular risk calculation in 
a much earlier stage. Therefore unlike previous eff orts in decision support systems we argue 
that the focus should not be on the rules and algorithms that guide these systems - this 
is contained in evidence based medicine itself - but rather on increasing the awareness of 
physicians in obtaining the relevant data. Giving eff ective feedback on the values in relation 
to cardiovascular risk might lead to better case fi nding of patients. Further research will have 
to show whether this approach is feasible and eff ective.
Conclusion          
In daily practice GPs seem to focus on secondary prevention of CVD. Intervention strategies 
that aim to infl uence GP’s case fi nding behaviour should focus on increasing the awareness 
of physicians in performing associated measurements in patients eligible for primary 
prevention of CVD. Further research will have to show the feasibility and eff ectiveness of such 
intervention strategies.
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Table 1 Associated measurements and prevalence of conventional risk factors for CVD one year after fi rst 
diagnosis of CVD*
Female Male
Age, mean(SD) 69.9 (12.5) 65.4 (12.5)
Measurements and risk factors, n(%)
Smoking measurement 372 (30.5) 585 (42.6)
Smoking 293 (24.0) 439 (32.0)
Glucose measurement 830 (68.0) 808 (58.8)
Diabetes Mellitus‡ 206 (16.9) 222 (16.2)
BP measurement‡ 1165 (95.5) 1298 (94.5)
Hypertension 568 (46.6) 489 (35.6)
Cholesterol measurement† 604 (49.5) 737 (53.6)
Hypercholesterolemia‡ 521 (42.7) 560 (40.8)
No. of Risk Factors‡ , n (%)
0 297 (24.3) 367 (26.7)
1 434 (35.6) 479 (34.9)
2 340 (27.9) 381 (27.7)
3 122 (10.0) 119 (8.7)
4 27 (2.2) 28 (2.0)
Total number of patients, n (%) 1220 (47.3) 1374 (52.7)
With at least one risk factor‡ 923 (75.7) 1007 (73.3)
* Risk factor prevalence diff erences between men and women in CVD subgroups statistically signifi cant at P<.001 unless 
otherwise noted
† Risk factor prevalence diff erences between men and women in CVD subgroups statistically signifi cant at P<.05
‡ Risk factor prevalence diff erences between men and women in CVD subgroups nonsignifi cant 
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Table 2 Timing of individual risk factor diagnosis in relation to fi rst diagnosis of a CVD event (n=2594)
Patients with 
risk factor
Risk factors related to the time of fi rst diagnosis of CVD
Risk Factors Before 
On the same day 
of diagnosis After 
N n % n % n %
Smoking 732 454 (62.0) 139 (19.0) 139 (19.0)
Diabetes Mellitus 428 334 (78.0) 10 (2.3) 84 (19.6)
Hypertension 1057 837 (79.2) 52 (4.9) 168 (15.9)
Hypercholesterolemia 1081 812 (75.1) 25 (2.3) 244 (22.6)
Table 3 Presence of cumulative number of the four risk factors as noted by the GP in relation to fi rst diagnosis of a 
CVD event (n=2594)
Risk factors related to the time of fi rst diagnosis of CVD 
Cumulative no. of risk 
factors per patients Before 
On the same day of 
diagnosis After 
n % n % n %
0 1031 (39.7) 893 (34.4) 664 (25.6)
1 880 (33.9) 951 (36.7) 913 (35.2)
2 518 (20.0) 566 (21.8) 721 (27.8)
3 139 (5.4) 156 (6.0) 241 (9.3)
4 26 (1.0) 28 (1.1) 55 (2.1)
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Table 4 Timing of associated measurements for individual risk factor in relation to fi rst diagnosis of a CVD event 
(n=2594)
Measurement
Patients with 
measurement
Measurements related to the time of fi rst diagnosis of CVD 
Before 
On the same day of 
diagnosis After 
N n % n % n %
Smoking 957 591 (61.8) 193 (20.1) 173 (18.1)
Glucose 1602 804 (50.2) 525 (32.8) 273 (17.0)
BP 2463 2059 (83.6) 241 (9.8) 163 (6.6)
Cholesterol 1341 966 (72.0) 29 (2.2) 346 (25.8)
Table 5 Presence of cumulative number of associated measurements for the four risk factors as noted by the GP in 
relation to fi rst diagnosis of a CVD event (n=2594)
Measurements related to the time of fi rst diagnosis of CVD 
Cumulative no. of 
measurements per 
patient Before 
On the same day of 
diagnosis After 
n % n % n %
0 412 (15.9) 155 (6.0) 62 (2.4)
1 1000 (38.6) 729 (28.1) 503 (19.4)
2 374 (14.4) 744 (28.7) 699 (26.9)
3 560 (21.6) 673 (25.9) 858 (33.1)
4 248 (9.6) 293 (11.3) 472 (18.2)
2594 (100.0) 2594 (100.0) 2594 (100.0)
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Abstract
Objective:  Screening, treatment and monitoring guidelines for hypertension and 
hypercholesterolaemia have been developed to assist physicians in providing evidence-based 
healthcare. We conducted a retrospective study to assess the management of patients with 
these single or combined conditions.
Research design and methods: This was a retrospective cohort study conducted using 
data from the Integrated Primary Care Information (IPCI) project based in the Netherlands. 
Management of hypertension and hypercholesterolaemia was assessed from 2000–2003 by 
measuring the numbers of patients screened for these conditions, treated pharmacologically, 
and monitored for treatment success.
Results: Approximately 11%, 3% and 10% of participants were eligible for screening for 
hypertension alone, hypercholesterolaemia alone and both conditions, respectively. Blood 
pressure screening was high in patients eligible for both blood pressure and cholesterol 
screening (>85%), whereas cholesterol screening was low (<56%). Among patients newly 
identifi ed with hypertension or hypercholesterolaemia who were eligible for pharmacotherapy, 
29% and 43%, respectively, were not treated within one year of diagnosis. Undertreatment 
was signifi cantly lower in patients with both conditions (24% and 37% for antihypertensive 
and lipid-lowering treatment, respectively, and 28% were not treated for both). Among newly 
treated patients, in the fi rst year of treatment there was no record of a blood pressure or 
cholesterol assessment, for 35% and 72%, respectively.
Conclusion: Management was sub-optimal in patients with hypertension or 
hypercholesterolaemia as well as in those with both of these conditions. The results of this 
study are likely to be widely applicable, particularly to other European and industrialised 
countries that have similar free-access health care systems to the Netherlands. 
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Introduction
Hypertension and hypercholesterolaemia are common, modifi able risk factors for cardio-
vascular disease (CVD), which is a leading cause of morbidity and mortality in industrialised 
countries1. The level of cardiovascular (CV) risk associated with concurrent hypertension and 
hypercholesterolaemia is far greater than the risk associated with either condition in isolation2. 
Long-term treatment of hypertension may substantially reduce the risk of myocardial infarction 
and stroke3; long-term use of lipid-lowering medications reduces the risk of coronary heart 
disease (CHD)4. Despite abundant evidence of the risks associated with hypertension and 
hypercholesterolaemia, and the proven effi  cacy of available treatments for these conditions, 
there is considerable underdiagnosis and undertreatment of these conditions.5–13.
The majority of previous studies have not addressed the overall management of hyperten-
sion and hypercholesterolaemia, and instead have focused on one aspect, such as screening 
or treatment. Furthermore, many of these studies have not assessed the concomitant manage-
ment of patients with both conditions5,6, 8, 10–14. Moreover, studies examining the undertreat-
ment of hypercholesterolaemia often have been based on selected secondary prevention 
populations or have been based on self-reported information11, 12,14,15. Previous studies in the 
Netherlands did not distinguish between undertreatment due to lack of prescribing or under-
treatment due to lack of persistence in taking medications5, 6, 11.
We conducted a retrospective study using a database containing general practitioner 
(GP) medical records. Our aims were to assess the extent of screening for, and pharmacological 
treatment of, hypertension and hypercholesterolaemia, and the extent of blood pressure (BP) 
and cholesterol monitoring in patients initiating treatment for one or both of these conditions. 
We then compared these fi ndings with the recommendations of the national guidelines for 
hypertension and cholesterol management16–18. Furthermore, we assessed the impact of the 
presence of concomitant hypertension and hypercholesterolaemia, versus either condition 
alone, on the management of these conditions.
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Patients and Methods
Database and study population       
Patient data were retrieved from the Integrated Primary Care Information (IPCI) project. The 
IPCI is a GP research database, containing longitudinal computer-based patient records (more 
than 500,000 patients in total) from 150 GPs in the Netherlands19, 20. The electronic records 
contain coded and anonymous data on patient demographics, symptoms (in free text), 
diagnoses by GPs and specialists (using the International Classifi cation for Primary Care21 and 
free text), referrals, laboratory fi ndings, clinical assessments, hospitalisations, and prescribed 
medications (including indications and dosage regimens). The IPCI system complies with the 
European Union guidelines on the use of medical data for research and has been proven valid 
for pharmacoepidemiological research20. The study was approved by the Scientifi c and Ethical 
Advisory Board of the IPCI project.
The study population comprised subjects aged ≥16 years, who had been registered for at 
least 1 year with their GP and whose GP had participated in the IPCI project for at least 1 year. 
The study period was from January 2000 to September 2003. Patients were followed until their 
death, transfer from the GP’s practice, or until the end of the study period. 
Screening          
Patient eligibility for, and the prevalence of, BP and cholesterol screening were assessed as of 
January 1, 2000 and January 1, 2002. Patient eligibility for screening was determined according 
to the 1999 Dutch College of General Practitioners (DCGP) clinical guidelines (Table 1) 16,17.  
Patients were considered to have their BP screened if they had a previous record of at least 
one BP measurement, a prescription for an antihypertensive medication, or a diagnosis of 
hypertension. Recommendations of current DCGP cholesterol guidelines include the screening 
of individuals with familial hypercholesterolaemia17. However, since this condition could not be 
assessed reliably for all subjects, it was not included in the analyses. Patients were considered 
to have had their cholesterol level screened if they had a previous record of at least one total 
cholesterol or total cholesterol/high-density lipoprotein (HDL) ratio measurement, a prescrip-
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tion for statin treatment, or a diagnosis of hypercholesterolaemia.
Identifi cation of hypertension and hypercholesterolaemia   
Hypertension was defi ned as: a recorded diagnosis by the patient’s GP or specialist; ≥2 BP 
measurements >160/95 mm Hg (in accordance with the 1999 DCGP guidelines); or antihyper-
tensive pharmacotherapy (thiazide, β-blocker, calcium channel blocker, angiotensin-converting 
enzyme inhibitor, or angiotensin II antagonist). 
Hypercholesterolaemia was defi ned as: a recorded diagnosis by the patient’s GP or 
specialist; total cholesterol >5 mmol/L (193 mg/dL); or treatment with a statin. The prevalence 
of hypertension alone, hypercholesterolaemia alone, and concurrent hypertension and hyperc-
holesterolaemia, was determined on January 1 of 2000, 2001, and 2002.
Newly identifi ed patients had no recorded evidence of hypertension and hypercholes-
terolaemia in their history. The earliest date that one of the hypertension criteria was identifi ed 
was considered as the index date for the onset of hypertension. Newly identifi ed patients with 
hypercholesterolaemia were determined in a similar manner. Among these cohorts, subgroups 
were identifi ed as: patients who were known to have hypertension at the fi rst diagnosis of 
hypercholesterolaemia, patients who had hypercholesterolaemia at the fi rst diagnosis of 
hypertension, and patients who were identifi ed with hypercholesterolaemia and hypertension 
within a period of 30 days.
Pharmacological treatment        
Only individuals with at least 1 year of follow-up data after the onset of hypertension or 
hypercholesterolaemia were included in the evaluation of treatment. At the index date, we 
assessed whether the patient was eligible for treatment, and if the patient was prescribed phar-
macological treatment within 1 year after the index date. The 1999 DCGP guidelines16, 17, which 
use the Framingham risk function to estimate CV risk22, were used to determine treatment 
eligibility (Table 1). The presence of concomitant CVD was determined from coded diagnoses. 
Risk factors for CVD were obtained from patients’ medical records and CV risk profi les. In the 
absence of total cholesterol/HDL ratios, which are necessary to calculate the Framingham risk 
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score, gender and age-specifi c reference values were imputed23. Also, since the thresholds for 
treatment eligibility in the Dutch guidelines omit left ventricular hypertrophy, this condition 
was not considered in this calculation.
The number of patients eligible for treatment at the index date, the proportion who 
received treatment within 1 year, and the proportion monitored for BP and cholesterol during 
the fi rst year following treatment initiation, were estimated.
Statistical analysis         
Descriptive statistical analyses were performed with SPSS version 11 (SPSS Inc., Chicago, 
IL, USA). Patient characteristics were summarised by mean and standard deviation (SD) for 
continuous variables and by percentage for categorical variables. Prevalences were summarised 
by mean and 95% confi dence intervals (CI). Chi-square tests were used to assess diff erences 
in the treatment and monitoring rates of patients with and without prevalent concomitant 
conditions.
Results
The source population with 1 year of valid history comprised 250,210 subjects aged ≥16 years 
(mean age 42.6 years, 50.6% female).
Screening          
Overall, the proportion of the population who were eligible for BP screening as of January 1, 
2000 and January 1, 2002 was slightly above 20% (Table 2). Fewer patients (approximately 13%) 
were eligible for cholesterol screening. The BP screening rate for patients who were eligible for 
both cholesterol and BP screening was considerably higher than in those patients eligible for 
BP screening alone (86.2% vs 50.8% in 2000). Also, the rate of cholesterol screening was higher 
in patients eligible for both types of screening compared with those eligible for cholesterol 
screening alone (50.2% vs 38.0% in 2000).
Despite little change in the proportion of patients who were eligible for screening from 
2000 to 2002, the proportion of patients who were screened increased slightly over this time 
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period (Table 2).
Prevalence          
The prevalence of concomitant hypertension and hypercholesterolaemia increased from 6.5% 
in 2000 to 8.1% in 2002 (Fig. 1). 
Pharmacological treatment        
We identifi ed 8495 new patients with hypertension and 10,451 new patients with hypercholes-
terolaemia. Among these patients, there were 964 in whom hypertension and hypercholestero-
laemia were identifi ed within a period of 30 days. Clinical and demographic characteristics at 
the index date are presented in Table 3. It is noteworthy that 23.6% of newly identifi ed patients 
with hypertension were known to have existing hypercholesterolaemia, and 45.9% of newly 
identifi ed patients with hypercholesterolemia were known to have existing hypertension. The 
estimated 10-year risk of CHD was, on average, 10.5%, 14.7%, and 12.9% among patients with 
newly identifi ed hypertension, hypercholesterolaemia, and both conditions newly identifi ed, 
respectively. 
The numbers of patients who were eligible for antihypertensive or lipid-lowering pharma-
cotherapy based on the 1999 guidelines (Table 1) and the proportions of these patients who 
received treatment within 1 year of diagnosis are shown in Table 4. Overall, undertreatment was 
substantial, with 28.7% and 43.1% of treatment-eligible patients not receiving treatment for 
hypertension and hypercholesterolaemia, respectively (Fig. 2A, 2B). Moreover, 27.9% of treat-
ment-eligible patients who were identifi ed with both hypertension and hypercholesterolaemia 
within 30 days did not receive treatment for both conditions (Fig 2C). Undertreatment rates for 
patients with prevalent concomitant hypertension and hypercholesterolaemia were signifi -
cantly lower than undertreatment rates in persons with a single condition (p < 0.001) (Table 4).
Monitoring during initial treatment      
Overall, 90% of the patients had at least one visit to their GP during the fi rst year of treatment. 
Approximately 65% of patients treated for hypertension had a BP measurement recorded 
in their fi rst year of treatment. Only 27.6% of patients treated for hypercholesterolaemia, 
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irrespective of the type of statin used, had a cholesterol level measurement recorded during 
their fi rst year of treatment (Table 4; Fig 2A, 2B). Among patients taking simvastatin (the only 
drug for which cholesterol monitoring is recommended [Table 1]) 25.4% had one or more 
recorded cholesterol measurements for this time period. Among patients newly identifi ed with 
both hypertension and hypercholesterolaemia and who were treated for both conditions, only 
16.7% had both their BP and cholesterol recorded (Figure 2C). Blood pressure and cholesterol 
monitoring rates did not diff er signifi cantly between patients with one condition only versus 
patients with both conditions (Table 4).
Discussion
This study demonstrates that the management of hypertension and hypercholesterolaemia is 
far from optimal across the entire management process (screening, treatment, and treatment 
monitoring) in primary care in the Netherlands. The prevalence of these conditions, as well as 
the prevalence of concomitant hypertension and hypercholesterolaemia is substantial and 
increased between 2000 and 2002. Furthermore, we observed that these two CV risk factors 
commonly coexisted. The reasons for this increase in the prevalence of hypertension and 
hypercholesterolaemia are uncertain, but could be related to increased screening for these 
conditions and ageing of the population.
Many patients who were eligible for BP and cholesterol screening were not screened. 
For example, by 2002 almost 30% of those eligible did not have their BP screened, and over 
45% of those eligible failed to have their cholesterol levels screened. These observations are 
surprising considering the extent of information regarding CV risk factors and events that was 
available in the patients’ medical records. However, the small increase in screening from 2000 
to 2002 and the increased levels of screening of patients with concomitant hypertension and 
hypercholesterolaemia (compared with those with just one of these conditions) indicates one 
area of improvement. Nevertheless, the reasons for this poor performance should be identifi ed 
and addressed.
Among treatment-eligible patients with newly identifi ed hypertension or hypercholestero-
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laemia, many did not receive pharmacotherapy for their condition within 1 year of their initial 
diagnosis (hypertension 29%; hypercholesterolaemia 43%). Monitoring rates among those 
initiating antihypertensive or lipid-lowering pharmacotherapy were also low (65% and 28%, 
respectively). The presence of concomitant hypertension or hypercholesterolaemia in these 
patients resulted in a small improvement in the rate of treatment but had no signifi cant eff ect 
on monitoring rates. Among patients newly identifi ed with both hypertension and hypercho-
lesterolaemia who were eligible for treatment, 28% did not receive pharmacotherapy for both 
conditions. In those initiating treatment for both conditions, only 17% had both their BP and 
cholesterol measured during the fi rst year of treatment.
Since GPs participating in IPCI are not allowed to maintain additional paper records, the 
low treatment and monitoring rates that we have observed here are likely to represent an 
accurate view of the state of management of hypertension and hypercholesterolaemia in the 
Netherlands.
Our study used the 160/95 mm Hg cut-off  points of the 1999 DCGP guidelines16 to defi ne 
hypertension. In the 2003 DCGP hypertension guidelines18, the cut off  point was lowered to 
140/90 mm Hg (Table 1), in accordance with World Health Organization/International Society 
of Hypertension (WHO/ISH) recommendations24. Therefore, whilst our assessment of patient 
management was based on the guidelines that were in place at the time of the study, the actual 
prevalence of hypertension and concomitant hypertension and hypercholesterolaemia using 
the current defi nition (140/90 mm Hg)18 was higher in this population (Fig. 1). This suggests that 
there were many patients who potentially could have benefi ted from pharmacotherapy but 
who were not recognised as being in need of treatment.
Despite a generally high acceptance rate of the DCGP guidelines among GPs19, low adher-
ence to these guidelines has previously been recognised. Grol et al25 found that many of the 
DCGP recommendations were followed in only 61% of clinical decisions. Aside from the issue of 
cost-eff ectiveness, which forms part of the DCGP cholesterol guidelines, there are a number of 
barriers that may prevent physicians from adhering to guidelines. These barriers may relate to 
a general lack of familiarity, awareness or agreement with the guidelines, or a lack of outcome 
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expectancy, self-effi  cacy, or motivation26–28. We expect that our results are infl uenced by all of 
these factors, but that certain aspects are more pertinent. For example, hypertension guidelines 
generally are easier to implement, because of the less invasive nature of the procedures 
involved, which may improve adherence. Eff orts to facilitate the implementation of guideline 
recommendations, particularly those for hypercholesterolaemia, are required urgently.
Previous studies conducted in a variety of locations and settings have assessed the extent 
of undertreatment of hypertension, hypercholesterolaemia or both conditions5−14, 29−40, and our 
results point to the same conclusion: undertreatment is extensive, even in patients who have 
both conditions and are therefore at increased risk for developing CVD. For example, similarly 
high rates of undertreatment of hypertension (30% for females and 47% for males) have been 
observed in a Dutch population-based survey conducted between 1987 and 1995 among 
individuals aged 20–59 years of age5. In our study, 31% of treatment-eligible patients over the 
same age range were undertreated. This level of undertreatment for hypertension at the 160/90 
mm Hg threshold is greater than that observed in the US in a survey completed in 1994 (22%), 
but less than that seen in surveys conducted in Canada (1986−92; 38%), England (1998;48%), 
Italy (1998;46%), Spain (1990; 54%), Sweden (1999; 51%) and Germany (1997−99; 59%)13. 
Recent studies conducted in the United Kingdom (UK), have indicated that  secondary 
prevention patients who are at high risk of further CVD events often do not have their 
cholesterol levels recorded (17% in a small study [n=300] and 51.7% for a much larger study 
[n=89,422])12, 37. Among patients who had their cholesterol level recorded only half were 
receiving statin therapy12,37. Furthermore, evidence from a range of studies conducted in both 
primary and secondary prevention populations suggests that patient receiving statin therapy 
are rarely titrated to the doses required to attain lipid treatment goals 7, 12, 34, 37. 
The treatment rates for hypercholesterolaemia in the present study are much higher than 
the results of the MORGEN (Monitoring Project on Risk Factors for Chronic Diseases) study, a 
1987–1997 Dutch population-based, cross-sectional study of individuals aged 20-59 years11. In 
the MORGEN study, 32% of individuals who were eligible for treatment (accounting for 5.5% of 
the total population with suboptimal cholesterol levels) were aware of their high cholesterol 
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levels, and only 16.3% of these treatment-eligible individuals were treated. Our higher treat-
ment rates (60.9% when restricted to the same age range as the MORGEN study) might point to 
an improvement in cholesterol management with time. Mantel-Teeuwissel15. observed a com-
parable increase in treatment rates with time, from 10% (1987–1992) to 45.9% (1998–2002). This 
increase in treatment rates for hypercholesterolaemia has been reported in studies in across 
Europe and in Australia7, 34, 35, 37, 38.  A slight increase in the use of antihypertensive medications 
was also reported between 1995−6 and 1999−2000 across 15 European countries8. However, 
unlike the results for hypercholesterolaemia, this increased utilization of antihypertensives was 
not associated with a decrease in the prevalence of hypertension8.
Blood pressure monitoring is recommended by the DCGP guidelines in patients starting 
antihypertensive therapy16,18. However, in this study, the rate of BP monitoring (65%) was lower 
than the 81% rate found in a similar observational setting in the United States41. 
The DCGP guidelines also advise that cholesterol should be tested 3 months after initiating 
treatment with simvastatin17. For statins other than simvastatin, cholesterol monitoring is not 
an explicit recommendation of the DCGP guidelines17. However, the rate of cholesterol monitor-
ing in patients on simvastatin treatment was very low and was similar to the rate of monitoring 
among patients treated with other types of statins. Most current international guidelines 
recommend the monitoring of hepatotoxicity in patients administered statin therapy, but not 
of cholesterol levels. This is inconsistent with the approach advocated regarding the monitoring 
of BP during antihypertensive treatment. As acknowledged in the DCGP cholesterol guidelines, 
persistence with therapeutic regimens is essential for successful treatment. Monitoring of 
laboratory levels is an eff ective way of ensuring patient adherence to treatment, and it is likely 
that the lack of follow-up cholesterol measurements could have a negative impact on persist-
ence with lipid-lowering treatment and the attainment of therapeutic goals. The low recorded 
monitoring rates observed in patients with both hypertension and hypercholesterolaemia 
suggest that there may be many missed opportunities to assess the status of these conditions 
and to provide appropriate follow-up care. 
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Limitations and validity        
Our study benefi ts from the fact that it used an observational database, which refl ects the GP’s 
daily actions without any intervention by researchers. However, our choice of working from the 
perspective of the GP also confers some limitations. For example, GPs do not screen or record 
all CV risk factors in all patients. Therefore, the number of patients eligible for screening and the 
number of patients with hypertension and/or hypercholesterolaemia will probably have been 
underestimated. Furthermore, the absence of data on patient smoking habits, the imputation 
of reference values on the total cholesterol/HDL ratio and assumptions regarding the presence 
of familial hypercholesterolaemia will have resulted in an underestimation of the number of 
patients eligible for treatment. Because of this, and the fact that there may be patients with 
elevated cholesterol and/or BP levels whose condition has not been recognised by their GP or 
who have not visited their GP, the rate of undertreatment may be considerably higher.
The results of this study should be widely applicable, particularly to other European and 
industrialised countries that have free-access health care systems. 
Conclusion          
Our study demonstrates the systematic underperformance that is present in the overall 
management of hypertension and hypercholesterolaemia in the Netherlands. Considering 
the high level of CV risk that is commonly observed in patients with both hypertension and 
hypercholesterolaemia, the latest DCGP guidelines provide a signifi cant opportunity to improve 
the management of patients with these conditions. Our approach has been to examine 
the management process using the information available to GPs, which has enabled us to 
highlight the disparity between guideline recommendations and actual practice. It is clear that 
a much greater eff ort is needed in fi nding ways to help physicians provide optimal screening, 
pharmacotherapy and monitoring of patients with hypertension, hypercholesterolaemia, and, 
in particular, both of these conditions.
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Fig. 1. Prevalence of hypertension, hypercholesterolaemia, and concomitant hypertension and hypercholesterolaemia. 
Dotted lines indicate the prevalences based on the 2003 hypertension guidelines. Vertical bars represent 95% 
confi dence intervals. Data labels show mean values.
 
Fig 2A. Antihypertensive treatment and blood pressure monitoring rates in patients with newly identifi ed hypertens
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Fig 2B. Lipid-lowering treatment and cholesterol monitoring rates in patients with newly identifi ed 
hypercholesterolaemia.
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Fig 2C. Antihypertensive and lipid-lowering treatment rates, and blood pressure and cholesterol monitoring rates in 
patients with newly identifi ed concomitant hypertension and hypercholesterolaemia.
*Treatment eligibility is based on the 1999 DCGP guidelines.
†The treatment rate is calculated as the percentage of treatment-eligible patients (with ≥1 year of follow-up data 
from diagnosis) who had a record of treatment within 1 year of diagnosis.
‡The monitoring rate is calculated as the percentage of treated patients (with ≥1 year of follow-up data from 
treatment initiation) who had a record of at least one measurement during the fi rst year of treatment.
§Graphs show estimated rates of treatment and monitoring calculated as a proportion of all newly identifi ed 
patients.
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Abstract
Backgound: Many studies have shown diff erences between statins based on surrogate 
endpoints, but few studied diff erences in reaching clinical endpoints.
Objective: We compared the risk of cardiovascular and cerebrovascular events between 
atorvastatin users and other statin users in daily general practice.
Research design and methods: We performed a cohort study in the Integrated Primary Care 
Information project database, a longitudinal general practice research database with electronic 
patient records of more than 500,000 individuals in the Netherlands. All new statin users in the 
period 1 September 1999 to 31 December 2002 were included. Multivariate Cox-regression 
analysis was used to compare the occurrence of the primary endpoint between atorvastatin 
users and other statin users.
Main outcome measures: The primary endpoint was the composite outcome of fatal or 
non-fatal myocardial infarction, admission for unstable angina pectoris, fatal or non-fatal 
cerebrovascular accidents, or transient ischemic events. 
Results: 3499 new statin users were identifi ed, including 797 patients with a history of 
cardiovascular disease. 1341 persons started with simvastatin (38%), 1154 with atorvastatin 
(33%), 811 with pravastatin (23%) and 193 with other statins (6%). The median follow-up 
was 1.9 years. Two hundred thirty three patients (6.7%) experienced a primary endpoint. 
Atorvastatin users had a signifi cantly lower risk of cardiovascular and cerebrovascular events 
than users of other statins (RR: 0.70, 95%CI: 0.55-0.96). The relative risks of atorvastatin users 
compared to simvastatin and pravastatin users individually were 0.70 (95%CI: 0.48-1.02) and 
0.78 (95%CI: 0.52-1.16), respectively. The protective eff ect of atorvastatin was more pronounced 
in persons without a history of cardiovascular or cerebrovascular events.
Conclusion: Atorvastatin showed a more favorable eff ect on fatal and non-fatal cardiovascular 
and cerebrovascular events in the general population than other statins.
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Introduction
Cardiovascular disease (CVD) due to atherosclerosis is a leading cause of death in western 
countries. Treatment with 3-hydroxy3-methylglutaryl coenzyme A reductase inhibitors (statins) 
has been widely accepted and implemented in most guidelines for patients with CVD and for 
primary prevention in patients at increased risk of CVD 1, 2. Statins exert their action by lowering 
the concentration of low-density lipoprotein cholesterol (LDL-C), an important modifi able 
risk factor for CVD 3-8. In addition statins have a benefi cial eff ect on the infl ammatory process 
believed to be involved in atherosclerotic plaque formation 5, 9-11. Large scale randomized 
clinical trials have shown clinical benefi t of statins in the treatment and prevention of CVD 12-19. 
Recently an observational study in the Untied Kingdom showed that the benefi cial eff ect of 
statins can be extended to all patients with coronary heart disease 20. 
Although all available statins have demonstrated effi  cacy, diff erences between individual 
statins exist. Rosuvastatin has been reported as being more effi  cacious than other statins in 
improving lipid profi les 21. The anti-infl ammatory eff ects of atorvastatin have been reported 
as more potent than that of other statins 22-24. In addition, the anti-oxidant properties of 
atorvastatin have been studied, and benefi ts attributed to the existence of active metabolites 10. 
Whereas achieving lipid-lowering goals by diff erent statins has been studied well 25-27, the ability 
of diff erent statins to actually reduce the CVD risk in daily practice has not been addressed to 
date. In the present study we compared atorvastatin with other statins on clinical endpoints in 
a primary care setting.
Patients and Methods
Setting          
The study was conducted in the Integrated Primary Care Information (IPCI) project database, 
a longitudinal general practice research database in the Netherlands. All residents in the 
Netherlands are registered with a general practitioner (GP) independent of their health 
status. The GP deals with 90% of the health problems and acts as the gatekeeper for access to 
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specialized care 28. The IPCI project was started by the Department of Medical Informatics of the 
Erasmus MC, University Medical Centre Rotterdam in the Netherlands. The database contains 
longitudinal data from computer-based patient records of more than 150 GPs throughout the 
Netherlands. Presently the database comprises data on more than 500,000 subjects (3% of the 
Dutch population), the age and gender distribution of whom is similar to the Dutch population.
Available data include anonymous eligibility and demographic information (age, sex, 
patient identifi cation, GP registration information), symptoms, diagnoses, specialist fi ndings, 
hospital admissions, prescriptions, indications for therapy, physical fi ndings and laboratory fi nd-
ings. The International Classifi cation of Primary Care (ICPC) is the coding system used to register 
patient complaints and diagnoses, although diagnoses and complaints can also be entered 
as free text. Prescription data include product name, quantity dispensed, dosage regimens, 
strength and indication. The National Database of drugs, maintained by the Royal Dutch 
Association for the Advancement of Pharmacy (KNMP), enables the coding of prescriptions 
according to the Anatomical Therapeutic Chemical (ATC) classifi cation scheme recommended 
by the World Health Organisation (WHO). The IPCI database system complies with European 
Union guidelines on the use of medical data for medical research and has been proven valid for 
pharmaco-epidemiological research 29. 
Study population         
The source population for this study comprised all subjects of 18 years and older with at least 
one year of valid database history. A valid database history means that the patient is registered 
with the GP and that the GP participates in the IPCI project. The study population consisted of 
all subjects from the source population who started their fi rst statin treatment during the study 
period (i.e. new users only). The study period for patient inclusion started on 1st September 
1999, when the cholesterol guideline from the Dutch GP-society (NHG) was issued, and ended 
on 31st December 2002. Follow-up lasted from the fi rst statin prescription until the occurrence 
of a study endpoint, 31st December 2003 or last IPCI data deliverance by the GP, whichever 
came fi rst.
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Statin treatment         
Statin use was identifi ed from the prescription fi les, which contain information on GP prescrip-
tions and repeat prescriptions from specialists. It was classifi ed as secondary prevention if a 
history of cardiovascular or cerebrovascular disease was present at baseline and as primary 
prevention if there was no history of cardiovascular or cerebrovascular disease. The analysis 
included atorvastatin, simvastatin, fl uvastatin and pravastatin. Cerivastatin was included, but 
was withdrawn from the market during the study period. We were unable to include rosuvasta-
tin, since there were insuffi  cient users at the time of analysis. 
Duration of treatment was calculated for each prescription as the number of prescribed 
units divided by the prescribed daily units. We also calculated the starting dosage of statin by 
multiplying the prescribed daily units by the prescribed unit strength of the fi rst prescription. 
The starting dose was expressed in defi ned daily dosage (DDD) equivalents according to 
the WHO criteria [ATC index with DDDs 2003, WHO Collaborating Centre for Drug Statistics 
Methodology, Oslo, Norway] in order to allow for comparisons between statins. As equivalence 
as assumed by the WHO not necessarily indicates equal potency, we additionally categorized 
the starting dose according to a recently published potency conversion table adapted from 
Maron and Illingworth based on the cholesterol lowering properties of diff erent statins given at 
a certain dose 30-32. For example, this table considers 10 mg atorvastatin, 20 mg simvastatin, 40 
mg pravastatin, 80 mg fl uvastatin and 0.4 mg cerivastatin as equipotent at a high potency (27% 
reduction in total cholesterol).
In order to take account of the potential infl uence of diff erences in the course of treatment, 
we assessed treatment discontinuation and switching behavior. Discontinuation of statin treat-
ment was defi ned as the absence of a new prescription for at least 6 months after the end of 
the last prescription. Switching was defi ned as the prescription of another type of statin within 
6 months of the end of the last prescription. We estimated adherence to statin treatment per 
individual statin as the number of days in a year that statins were prescribed for, divided by the 
number of days of follow-up in that year, censored for treatment discontinuation and switching.
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Study endpoints         
As primary outcome of our study we considered a composite of cardiovascular and cerebrovas-
cular outcomes comprising fatal and non-fatal myocardial infarction, acute hospital admission 
for angina pectoris, fatal and non-fatal cerebrovascular accidents and transient ischemic attack. 
As a secondary outcome measure we looked at cardiovascular events only, thereby ignoring 
cerebrovascular accidents. All diagnoses occurring in the database, either as free text or as 
ICPC code were considered and reviewed in the patient records by two medically qualifi ed 
investigators who were blinded for relevant exposure. In addition, we described the cholesterol 
lowering eff ect of statins as the maximal reduction in cholesterol/HDL ratio within 6 months 
after starting statin treatment for patients with an elevated ratio at baseline (ie. cholesterol/HDL 
>5). 
Co-variates          
Apart from statin use we considered other potential risk factors for cardiovascular and cer-
ebrovascular events, such as age, gender, health care insurance, history of cardiovascular and 
cerebrovascular disease, presence of diabetes mellitus, hypertension or antihypertensive treat-
ment, cholesterol/HDL ratio, smoking and Framingham risk score 33. Where missing in subjects 
treated for primary prevention we imputed average population values of the cholesterol/HDL 
ratio for calculation of the Framingham risk score 34.
Analysis          
Baseline diff erences between statin users were tested by using a Pearson’s Chi-square for 
categorical variables, T-test for continuous normally distributed variables and Mann-Whitney 
U for continuous skewed variables. The diff erence in risk of cardiovascular and cerebrovascular 
events between statins was analyzed by using univariate and multi-variate Cox-regression 
analysis. Since the median follow-up time was 1.9 years, we censored the analysis at 2 years. 
In the analysis we compared atorvastatin, being the statin with the highest LDL-C reducing 
potency, to other statins individually and as one reference group. Multivariate or adjusted 
analysis included all co-variates that were associated with the primary endpoint at a p-value 
Chapter 5
80
of 0.1 and all other known risk factors for the study outcome. Since total cholesterol and HDL 
measurements are rarely performed in daily practice, we used missing indicators for missing 
cholesterol/HDL ratios in the analyses. In the Cox-model, exposure to statin treatment was 
principally considered as intention-to-treat, thereby ignoring treatment discontinuations 
and switches. To evaluate the infl uence of treatment discontinuation and switching we 
also performed an as-treated-analysis in which follow-up was additionally censored upon 
discontinuation or switching. In an exploratory analysis we also compared the eff ect of statins 
between persons treated for primary prevention and persons treated for secondary prevention 
and performed a sensitivity analysis with cardiovascular events as the only study endpoint.
Statistical signifi cance was accepted at a two-sided p-value of <0.05. All statistical analyses 
were performed in SPSS version 10.0.
Results
Patient population         
Between September 1999 and December 2002, 3499 persons started treatment with a statin, 
1341 on simvastatin (38%), 1154 on atorvastatin (33%), 811 on pravastatin (23%) and 193 
on other statins (6%). Patient characteristics are summarized in table 1. In brief, 43% were 
female, the mean age was 60.6 (SD 11.6) years, and 22.8% had a prior history of cardiovascular 
or cerebrovascular events. Cholesterol/HDL ratios were available for 569 (16%) patients. The 
median ratio was 5.0 (inter quartile range [IQR]: 3.9-6.3) and accordingly 280 (49%) patients had 
a ratio above 5.0. With respect to relevant patient characteristics the following diff erences were 
found between users of various statins. There were more females among fl uvastatin users and 
more males among cerivastatin users than among atorvastatin users. Pravastatin users were 
slightly older, more often had a history of cardiovascular or cerebrovascular disease and more 
often had cholesterol/HDL levels above 5. There were more smokers among simvastatin users. 
Fluvastatin and cerivastatin were given at relatively lower dosages. Overall, the potency of the 
prescribed atorvastatin regimens was higher than that of other statins (Table 1). 
Patients contributed a total of 6862 years of follow-up with a median duration of 1.9 years 
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(IQR: 1.2-2.7). 
Statin treatment         
The total number of treatment days on statins during the fi rst year of follow-up accumulated 
to 1469 years with a median of 160 days per patient (IQR: 90-215). Forty-six percent of patients 
did not persist with the initial treatment during the study period, mainly due to discontinuation 
(82.5%). The rate of non-persistence with atorvastatin was lower than with fl uvastatin (p=0.001) 
and cerivastatin (p<0.001) but similar to simvastatin and pravastatin. It should however be 
noted that cerivastatin was withdrawn from the market during the study period.
Overall adherence with statin use was low but was similar for all statins. The median 
adherence was 55.7% (IQR: 35.3-72.9), which means that patients had statins available for 
55.7% of the follow-up time based on prescription refi lls issued until treatment discontinuation, 
switch or the end of follow-up. The median daily dosage used at treatment initiation was 10 mg 
for atorvastatin, 20 mg for simvastatin, and 40 mg for pravastatin, corresponding to more than 
1 DDD of simvastatin and pravastatin (Table 1). 
Study endpoints         
During follow-up 233 patients experienced a cardiovascular or cerebrovascular event, 102 
(43.8%) of whom following a history of cardiovascular or cerebrovascular disease. Events 
comprised non-fatal myocardial infarction (n=75), fatal myocardial infarction (n=20), hospital 
admission for instable angina pectoris (n=56), non-fatal cerebrovascular accident (n=35), fatal 
cerebrovascular accident (n=3) and transient ischemic attack (n=44). Atorvastatin users had 
the lowest one-year risk of cardiovascular and cerebrovascular events (hazard rate 3.10 per 100 
persons, 95%CI: 2.08-4.12) and fl uvastatin users had the highest risk (Figure 1). The two-year 
risks were 5.24 (95%CI: 3.82-6.65) for atorvastatin, 6.69 (95%CI: 5.22-8.16) for simvastatin, 7.59 
(95%CI: 4.26-10.92) for pravastatin, 10.35 (95%CI: 4.25-16.45) for fl uvastatin and 10.54 (95%CI: 
3.54-17.54) for cerivastatin.
Risk factors for cardiovascular and cerebrovascular events in our study population included 
age, gender, history of cardiovascular disease and cholesterol/HDL ratio above 5 (Table 2). 
Chapter 5
82
Including these in the multivariate analysis together with other known risk factors (smoking, 
diabetes, hypertension and number of defi ned daily doses) resulted in an adjusted RR of 0.70 
(95%CI: 0.55-0.96) for atorvastatin compared to other statins together (Table 3).  Comparing 
atorvastatin to each individual statin separately showed a statistically non-signifi cant lower risk 
of cardiovascular and cerebrovascular events than pravastatin (RR: 0.78, 95%CI: 0.52-1.16) and 
simvastatin (RR: 0.70, 95%CI: 0.48-1.02) and a statistically signifi cant lower risk than fl uvastatin 
(RR: 0.38, 95%CI: 0.19-0.76) and cerivastatin (RR: 0.41, 95%CI: 0.20-0.88).
In the as-treated analysis, in which we additionally censored upon treatment switch or 
discontinuation, the protective eff ect of atorvastatin relative to other statins remained the same 
(RR: 0.70, 95%CI: 0.50-0.97). Stratifi cation for primary or secondary prevention showed a more 
favorable eff ect of atorvastatin in the group treated for primary prevention (RR: 0.61, 95%CI: 
0.39-0.97 n=2702) than in those treated for secondary prevention (RR: 0.82, 95%CI: 0.51-1.30; 
n=797) but the eff ect-modifi cation was not statistically signifi cant. Restricting the outcome 
to cardiovascular events lowered the RR estimate slightly (atorvastatin versus other statins 
adjusted RR: 0.65, 95%CI: 0.43-0.97).
Out of 280 patients with a baseline cholesterol/HDL ratio above 5, only 78 (28%) had 
a repeat measurement within 6 months. Cholesterol/HDL ratio reduction to below 5 was 
achieved in 54% of atorvastatin users, 55% of simvastatin users, 46% of pravastatin users, 40% 
of fl uvastatin users and 33% of cerivastatin users (p=0.904).
Discussion
The results of this observational population based cohort study suggest that atorvastatin is 
associated with a lower risk of cardiovascular and cerebrovascular events than other statins 
under uncontrolled everyday circumstances of a primary care setting. This fi nding was not 
infl uenced by known risk factors for cardiovascular and cerebrovascular disease such as age, 
gender, diabetes, smoking and a prior history of cardiovascular or cerebrovascular disease and 
remained in an as-treated analysis. The diff erence seemed most pronounced in subjects who 
were treated for primary prevention and was greatest compared to fl uvastatin. A 30% statisti-
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cally non-signifi cant risk lower risk was observed with atorvastatin compared to simvastatin 
and pravastatin. Restriction of the outcome to cardiovascular events increased the observed 
diff erences.
In contrast to the controlled conditions and well defi ned populations in the clinical trial 
setting, which repeatedly demonstrated the benefi cial eff ects of statins, our data were derived 
from a primary care setting under every day circumstances. Only one earlier study reported the 
eff ect of statins in such a setting 20. They concluded that the benefi cial eff ect observed in clinical 
trials is also observed in the primary care setting. Our data further suggest a diff erence between 
individual statins.
The short-term preventive eff ect of atorvastatin appears to be substantial as shown 
in our study and is in keeping with other studies 35-38. It is unknown whether the reported 
anti-oxidant and anti-infl ammatory properties of atorvastatin 10, 22-24 can explain the observed 
early reduction in cardiovascular events. It would support the dynamic model of atheroma 
plaque formation and ruptures, which suggests that anti-infl ammatory treatment can produce 
immediate vascular wall protection 39, 40. On the other hand, diff erences in cholesterol lowering 
properties between statins may account for the observed diff erences in clinical eff ect. Our data 
showed acceptable cholesterol/HDL ratio reductions in approximately half the population with 
elevated ratios at baseline. There were no signifi cant diff erences between statins. However, we 
cannot draw any fi rm conclusions from this observation since cholesterol measurements were 
very infrequent and our study was not powered to examine small diff erences.  
This observational cohort study using data from a primary care setting may have 
important limitations. Although there is no reason to believe from current data that statins are 
prescribed diff erentially between persons with diff erent cardiovascular risk profi les, we cannot 
completely exclude the presence of confounding by indication. However, the distribution of 
baseline characteristics and known risk factors did not point at a consistently diff erent patient 
type among the statins. Nevertheless, since atorvastatin is supposed to have unique cardio-
vascular benefi ts in addition to its LDL lowering potency it could theoretically be prescribed to 
persons with a higher risk. Hence confounding by indication, if any, would work in the opposite 
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direction of our fi ndings. Misclassifi cation of exposure and of exposure duration is of no major 
concern in the intention-to-treat analysis. Misclassifi cation of outcome may have occurred in 
terms of omitting events in the GP record. Such misclassifi cation is unlikely to be diff erential 
between diff erent statins, since review of potential cases was blinded for the exposure under 
study and the research question, and data in the IPCI database are collected for health care 
purposes independently of any research question studied in the database.
Finally, it may seem odd that some known risk factors for cardiovascular and cerebrovas-
cular events, such as diabetes and hypertension, did not appear as a risk factor in our analysis. 
It should however be noted that we investigated a sample from the general population already 
treated with statins by the GP. The risk profi le of such a population is not comparable with 
the risk profi le of an untreated population. All our patients have risk factors for cardiovascular 
disease for which reason they received statin treatment.
Conclusions          
In conclusion, this study suggested a favorable eff ect of atorvastatin compared to other statins 
in the prevention of fatal and non-fatal cardiovascular and cerebrovascular events in the gen-
eral population. The risk reduction was observed across all statins, but only reached statistical 
signifi cance if compared to all statins together and to fl uvastatin and cerivastatin individually. 
The observed eff ect was most pronounced in primary prevention and mostly driven by the 
prevention of cardiovascular events. 
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Table 1 Baseline characteristics of patients starting statin treatment according to type of statin
 
Atorvastatin 
(n=1154)
Simvastatin 
(n=1341)
Pravastatin 
(n=811)
Fluvastatin 
(n=102)
Cerivastatin 
(n=91)
Sex (%)
Female 41.9 44.7 41.4 54.9a 30.8a
Male 58.1 55.3 58.6 45.1a 69.2a
Age (years, %)
<=53 28.5 29.2 23.2b 17.6 27.5
54-61 24.8 23.9 24.2b 26.5 25.3
62-69 24.2 22.7 23.8b 28.4 22.0
>=70 22.5 24.2 28.9b 27.5 25.3
Known risk factors (%)
Diabetes 24.0 25.9 21.6 27.5 18.7
Hypertension 31.4 32.3 32.4 36.3 27.5
Hypertension treatment 5.5 6.0 6.2 2.9 3.3
History of CVD 19.2 21.8 30.5c 20.6 16.5
Cholesterol/HDL >5 (real 
values only, n=569) 49.2 43.7 61.4a 59.3 26.3
Median values [IQR]
5.0 [3.9-
6.3]
4.8 [3.8-
6.0]
5.9 [4.2-
7.0]a
5.8 [4.4-
7.0]
4.3 [3.3-
5.2]a
Smoker 30.7 36.0b 30.8 36.3 20.9a
Median Framingham risk 
score [IQR] 12 [7-18] 12 [7-18] 13 [7-19] 13 [8-21] 11 [6-17]
Median dose [IQR] (n=3475)
Ddd 1.0 [1.0-2.0] 1.3 [1.3-1.3] 2.0 [1.0-2.0]c 1.0 [0.5-1.0]c 1.0 [1.0-1.8]c
Mg 10 [10-20] 20 [20-20] 40 [20-40] 40 [20-40] 0.2 [0.2-0.4]
Potency* (n=3455)
2: Low 0.0 0.0c 6.7c 27.7c 10.5c
3: Medium 0.0 16.9c 25.3c 54.5c 63.2c
4: High 53.3 72.1c 66.6c 17.8c 26.3c
5 37.4 10.6c 1.4c 0.0c 0.0c
6 8.7 0.4c 0.0c 0.0c 0.0c
7 0.6 0.0c 0.0c 0.0c 0.0c
Bold print represents statistically signifi cant diff erence with atorvastatin: a p=0.01 to 0.05, b p=0.005, c p<0.001 ; IQR = Inter Quartile Range; CVD = 
cardiovascular or cerebrovascular disease; DDD = defi ned daily dose; *according to Goettsch et al.30
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Table 2 Risk factors for cardiovascular and cerebrovascular events
 RR* 95%CI
Sex
Female 1 Reference
Male 1.29 [0.96-1.72]
Age (years)
<=53 1 Reference
54-61 1.02 [0.65-1.59]
62-69 1.40 [0.92-2.11]
>=70 1.87 [1.26-2.74]
Known risk factors
Diabetes 0.93 [0.66-1.30]
Hypertension 1.26 [0.94-1.68]
Hypertensive treatment 0.91 [0.43-1.93]
history of CVD 3.04 [2.29-4.01]
Cholesterol/HDL >5# 1.8 [0.68-4.52]
Smoker 1.02 [0.75-1.37]
Framingham risk score (per unit increase) 1.03 [1.01-1.05]
* Univariate Cox regression analysis; # based on real values (n=569)
CVD = cardiovascular or cerebrovascular disease
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Table 3. Association between statin use and the risk of cardiovascular and cerebrovascular events
 # Events 
within 2 years
Crude analysis Adjusted analysis*
 RR 95%CI RR 95%CI
Type of statin
Atorvastatin versus other statins 52 0.70 [0.50-0.95] 0.70 [0.50-0.96]
daily dose (n=3475)
 <1 DDD 17 0.81 [0.47-1.36]
 1-1.99 DDD 99 0.82 [0.61-1.10]
 >=2 DDD 79 1 reference
Potency (n=3455)
Low 6 1.11 [0.47-2.62]
Medium 35 1.13 [0.72-1.78]
High 113 0.91 [0.63-1.30]
Highest groups 39 1 reference
Primary prevention (n=2702)
Atorvastatin versus other statins 27 0.62 [0.40-0.96] 0.61 [0.39-0.97]
Secondary prevention (n=797)
Atorvastatin versus other statins 25 0.92 [0.58-1.47] 0.82 [0.51-1.30]
Atorvastatin versus 52
Simvastatin 76 0.78 [0.55-1.11] 0.70 [0.48-1.02]
Pravastatin 51 0.65 [0.44-0.96] 0.78 [0.52-1.16]
Fluvastatin 10 0.45 [0.23-0.88] 0.38 [0.19-0.76]
Cerivastatin** 8 0.51 [0.24-1.08] 0.41 [0.20-0.88]
* Cox regression analysis adjusted for type of statin, gender, smoking, diabetes, hypertension, history of cardiovascular or cerebrovascular disease, 
daily dose and cholesterol/HDL ratio above 5 (real values and missing indicator used)
DDD = defi ned daily dose
** Cerivastatin was withdrawn from the market during the study period
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Figure 1. Kaplan Meier diagram of survival until fatal or non-fatal cardiovascular or cerebrovascular events within 
two years after starting statin treatment (A = atorvastatin; S = simvastatin; P = pravastatin; C = cerivastatin; F = 
fl uvastatin)
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Abstract
Cardiovascular disease (CVD) is the leading cause of mortality in industrialized countries. 
Researchers report low primary and secondary prevention performance of physicians: they 
only seem to monitor and treat conditions in isolation (like hypertension or diabetes mellitus) 
without translating the measurements of single conditions to overall cardiovascular risk 
management. To improve both primary and secondary prevention of CVD, we developed the 
decision support system CholGate, based on the guidelines of the Dutch College of General 
Practitioners. Taking advantage of the use of electronic health records (EHR) by Dutch general 
practitioners, CholGate is integrated within the EHR to provide decision support in the 
clinician’s workfl ow. We discuss the underlying knowledge base of the system. Secondly, we 
highlight issues in gathering relevant patient data to identify patients at risk. Thirdly, we discuss 
the system’s user interface and workfl ow impact, and, fi nally, we focus on special considerations 
in implementing the system. 
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Introduction
Cardiovascular disease (CVD) is the leading cause of mortality in industrialized countries 1. 
Modifi able risk factors for developing CVD include smoking, diabetes mellitus, hypertension, 
and abnormal blood lipids. Evidence exists that managing these modifi able risk factors in 
primary care plays an important role in decreasing the morbidity and mortality due to CVD 
2, 3. Identifying and managing the modifi able risk factors for CVD before the onset of CVD, 
so-called primary prevention, is becoming more important in primary care 4. However, getting 
this evidence into practice is a major challenge. To deal with the rapidly expanding amount 
of medical knowledge, guidelines are increasingly viewed as a mechanism for distributing 
knowledge to practitioners 5, 6.
A number of studies have shown that the availability of guidelines does not necessarily 
lead to the use of these guidelines by physicians. Even when authoritative guidelines are 
available, changing the behaviour of physicians has proved to be diffi  cult 7, 8. In daily practice, 
for example, Dutch general practitioners (GPs) seem to start performing preventative activities 
after being confronted with a trigger event, so-called secondary prevention, although well 
defi ned guidelines for primary prevention are available 9. Physicians only seem to monitor and 
treat conditions in isolation (like hypertension or diabetes mellitus) without translating the 
measurements of that individual condition to an overall cardiovascular risk profi le management 
10.
An eff ective strategy for guideline implementation is integrating guideline based clinical 
decision support systems (CDSS) into the electronic health record (EHR) 11, 12. The objective of 
these systems is to help the physicians in making guideline-based decisions at the point of care. 
To improve both primary and secondary prevention of CVD, we developed the CDSS 
CholGate, based on the guidelines of the Dutch College of General Practitioners (DCGP). We 
fi rstly discuss the underlying knowledge base of the system. Secondly, we highlight issues in 
gathering relevant patient data to identify patients at risk. Thirdly, we discuss the system’s user 
interface and impact on workfl ow, and fi nally, we focus on special considerations in implement-
ing the system.
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Designing and implementing the system
The knowledge base         
In the Netherlands, the DCGP develop evidence-based guidelines for the primary care domain; 
these guidelines generally have a high acceptance rate among GPs 13. We used the six DCGP 
practice guidelines that deal with CVD risk factor management to construct the system’s 
knowledge base14. These guidelines centre on two main decision points for CVD risk factor 
management in primary care: Identifying patients who need to be screened and identifying 
screened patients who need to be treated.
Identifying patients who need to be screened     
The Dutch guidelines emphasize the need to screen specifi c, well-defi ned populations. As a 
result, the guidelines contain detailed, sometimes complex descriptions of the various condi-
tions that should lead to screening a patient 9. For example, a 45 year old male who smokes, has 
diabetes mellitus, and hypertension should be screened. If that same patient does not smoke, 
however, the guideline recommends abstaining from screening.
When a patient is identifi ed as eligible for screening, the guidelines recommend specifi c 
actions. These actions, however, depend on the patient’s current risks. For example, a patient 
with diabetes mellitus needs measurement of blood pressure, cholesterol/HDL ratio, and 
smoking habits. However, a patient younger than 50 who smokes and has no other risk factors 
for CVD needs no additional measurements. Once a patient is screened, the guidelines suggest 
various treatment options.
Identifying patients to be treated        
The guidelines distinguish between primary and secondary treatment decisions. The DCGP 
guidelines require calculation of a risk score for every patient who needs primary prevention. 
This risk score is based on the Framingham risk function for CVD 15. In the current paper-based 
guidelines, the score is deduced from a series of tables stratifi ed by age, gender, diabetes 
mellitus, systolic blood pressure, smoking, and cholesterol/HDL cholesterol ratio. For every age 
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group a threshold Framingham score exists where treatment is recommended. Diff erent colours 
in the tables are used to aid the physician: green meaning no treatment, orange meaning 
treatment is needed if there is a family history of coronary heart disease before the age of 60, 
and red indicating treatment. 
In secondary prevention, the treatment decision is more straight-forward. Any patient with 
CVD attributed to atherosclerosis and with a serum cholesterol level greater than 5mmol/l (193 
mg/dL) should be treated with statins. 
Finally, any patient with an abnormally high serum lipid value (Cholesterol > 9 mmol/l or 
Cholesterol/HDL ratio > 8mmol/l or Triglyceride >4mmol/l) should be referred to a specialist. 
Information retrieval        
CholGate retrieves and interprets data (e.g. diagnoses, risk factors, or laboratory measurements) 
from the electronic health record (EHR). This task of retrieving and interpreting data, however, 
is non-trivial: The CDSS is dependent on the way the physician has entered the data in the 
EHR. Information retrieval is facilitated when the physician enters data according to national 
or international classifi cation systems. Physicians, however, enter data not only according to 
international standards but also in self defi ned codes or free text. We distinguish, therefore, 
three categories of data the CDSS has to deal with. Firstly, coded data relies on widely used 
coding schemes to record data. In our system, this consists of the International Classifi cation for 
Primary Care (ICPC) for coding diagnoses and the Anatomical Therapeutical Classifi cation (ATC) 
16 for coding medication. Secondly, structured data relies on locally defi ned coding schemes 
(that is, each individual practice has their own coding scheme). In our system, this involved 
identifying on the level of an individual practise the codes used for specifi c conditions or 
measurements (e.g. constructing a local conversion table for laboratory measurements). Thirdly, 
free text data consists of data recorded in free text. In our system, we rely on the behaviour of 
physicians who, in busy daily practice, often use repetitive free text in their medical narrative17. 
Using this principle of recurring free text, we construct for individual users specifi c profi les 
containing the free text entries specifi c to that user. For example, a user might use “smoking +” 
in the record, indicating smoking where another user might use “smoker”. 
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Coded data are similar across diff erent practices. The use of structured data, however, 
requires the system to be tuned to each individual practise. Furthermore, the use of free text 
data requires the system to be tuned to an individual practitioner in that practice. 
The system will use the available data to assess the patient’s condition. In this process, 
the system may infer certain conditions to be present in the light of the guidelines, while the 
physician has not (yet) recoded that entity. For example, when an average of consecutive 
blood pressure measurements in six months is higher than 140/90 mmHg, the system assigns 
the label hypertension the patient, while the physician has not (yet) recorded that diagnosis. 
Similarly, diabetes mellitus is inferred if insulin prescriptions are issued. As shown in Figure 1 
for hypertension, the distinction between the data directly retrieved from the EHR and the 
data inferred based on the available data in the EHR is always explicitly displayed in the user 
interface. 
CholGate user interface and system integration     
The CholGate system is integrated within two widely used EHRs in the Netherlands: Elias (Isoft 
BV) and HetHis (Microbias BV). The general practitioners use these systems during consulta-
tion. Data are entered in the record by the physicians themselves during the patient contact. 
Because CholGate is tightly integrated with these EHRs, the system is easily accessible by the 
physician. The user interface of the CDSS is identical to the user interface of the host system – as 
a result, navigation and use of the system are already familiar to the user (e.g., entering data, 
selecting functions, fi nding help text etc.)
The essence of the system is to continually update the patient specifi c CVD risk profi les and 
recommend appropriate actions. To achieve this, the system continually retrieves key variables 
and displays them. The physician can change existing variables or add new data; these changes 
are subsequently included in the EHR. If the recommendation is an order (e.g. laboratory test) 
the system initiates that order (e.g by creating appropriate patient specifi c lab form to print). 
Any the change in the available results in an updated risk profi le.
CholGate supports two methods of interfacing with the user. First, the user decides when 
decision support is needed and then activates CholGate we call this order entry method. 
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Alternatively, the user is alerted when advice is available on a patient, so called alerting 
method. In alerting method, the system does not require the physician’s decision to activate 
the system but alerts the physician when screening or treatment is needed based on the data 
in the medical record. The method of interaction with the user is independent of the content of 
the knowledge base; that is, in both methods, the system relies on exactly the same knowledge 
base.
Implementation issues        
The fact that the system is tightly integrated with the EHR in a given site has consequences 
for the implementation of CholGate in a specifi c site. Whereas coded data is similar across 
diff erent sites, structured data refl ect local practices of that specifi c site, and free text data 
refl ect the practices of individual users of the system. As a result, the system needs to be tuned 
to both a local practice and the recording behaviour of the individual practitioner. For coded 
data, we identifi ed all relevant entries in the ICPC and ATC classifi cation systems. Structured 
data is identifi ed in each individual practise by creating a mapping of all structured data to the 
CholGate system (fi gure 2.) Free text data is identifi ed for every specifi c user by querying the 
user what free text they use. All mapped coded data and free text data can be reviewed and 
changed at any time by users. The setup process takes on average 30 minutes per practice.
Slow responses of systems may have a negative impact on the eff ectiveness and usability 
of systems 12, 18. After the author confi gures the initial conversion table, the system performs an 
optimization routine. This routine calculates the CVD risk profi le for every patient and attaches 
it to the patient’s record prior to the patient encounter. In this way, we increase performance 
of the system by preventing delays in searching and processing information during patient 
contact. Additionally, CholGate pre-fetches all relevant data connected to a patient that is not 
directly entered by a physician. For example, blood results are automatically downloaded from 
the pathology laboratories and used to update the CVD risk profi le for that patient.
Discussion
We developed the CholGate decision support system to improve primary and secondary 
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prevention of CVD in the setting of primary care. 
For primary and secondary prevention of CVD, the DCGP developed several guidelines in 
the Netherlands. These guidelines aim to assist the GP in providing evidence-based care. The 
DCGP guidelines are viewed as authorative and have a high acceptance rate13. However, having 
authorative and well accepted guidelines available does not directly translate into compliance 
to guidelines. Although the guidelines stress the importance of primary prevention, Dutch GPs 
tend to focus on secondary prevention of CVD in spite of the availability of suffi  cient relevant 
information 10. Adherence to the DCGP cholesterol guideline in primary practice is low, mainly 
due to the complexity of the guideline and interruption of the workfl ow process of the general 
practitioner 19. The essence for developers of a CDSS, therefore, is not building or constructing a 
new guideline, but rather using well accepted guidelines and integrating the recommendations 
and goals of these guidelines into the workfl ow of care providers.
The fi rst step when integrating a guideline within the workfl ow of a physician is to inte-
grate the recommendations of the guideline with the data in the EHR. Implementing guidelines 
across diff erent platforms (that is, diff erent GP information systems) and across diff erent 
institutions (that is, multiple practices) requires tailoring the system to these diff erent environ-
ments. Other researchers have discussed this issue; the developers of the Arden syntax, for 
example, use the term “curly brackets” 20 to denote the need for defi ning local mappings from 
variables in the electronic patient record to variables known to the CDSS. In the development of 
CholGate, we distinguish three diff erent types of data that need to be extracted from the EHR: 
coded data, structured data and free text. Coded data are similar across diff erent platforms, 
structured data are similar for all practitioners in one setting, and free text are specifi c for each 
individual user. The consequence of such an integrating of the CDSS with the local environment 
results in tailoring the system to each environment, including each individual user. The fact that 
time and eff ort are required for that integration, therefore, is a direct consequence of the need 
to integrate the system to the local work fl ow.
In addition to mapping the input data of the CDSS to the local setting, we also constructed 
the system taking into account several determinants that appear to be critical to the successful 
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introduction of CDSS in daily practice 18:  providing automatic support as part of the clinician’s 
workfl ow, providing decisions at the point of care, providing recommendations rather than just 
assessments, and providing computerized decision support. Firstly, CholGate provides auto-
matic decision support as part of the clinician’s workfl ow. When constructing the system, we 
had to be aware not only of the various decisions we had to support, but also on the impact our 
system would have on the workfl ow of the physician. We feel it is not appropriate to suggest 
an action to a physician without providing an extra incentive to follow that suggestion. For 
example, if the system identifi es a patient who needs screening, the physician has the option to 
print a patient specifi c laboratory order form including the recommended test(s); this prevents 
any double actions by the physician. Secondly, CholGate provides the decisions at the time and 
location of decision making. In a busy daily practice, a physician generally does not stop and 
or change the direction of the consult to interact with a CDSS 21. Because CholGate is tightly 
integrated with an EHR, constantly retrieving information for specifi c patients and evaluating 
CVD risk, the system is optimized to give decision support at the time when the physician in-
teracts with the computer regarding a specifi c patient. As a result, the system provides decision 
support when it is at its most relevant: during patient encounter. Thirdly, CholGate provides 
recommendations rather than just assessments. CholGate does not only provide assessments 
of the patient’s condition, but provides, if needed for that specifi c patient, the relevant action(s) 
that should be taken. To avoid overloading the user with recommendations (leading to the 
users ignoring or not using the system; a phenomenon called alert fatigue) the system only 
provides alerts when an action needs to be taken during this patient encounter. Additionally, 
once a user has seen an alert, the alert disappears for that session. The user can always ignore 
the alert and continue the consultation.
Kawamoto et al could not comment on system speed as a factor in infl uencing physician 
due to the paucity of studies that specifi cally addressed this issue. Taking into account reported 
failures of CDSS by slowing the physician, we optimized the system for speed as much as 
possible.21, 22.
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Limitations of the system        
Tightly integrating a CDSS with many various EHR’s in the Netherlands is diffi  cult. Therefore, 
the system is currently only running on two of the six available EHR platforms in Dutch primary 
care. At the time of writing, 60 Dutch general practices including 120 general practitioners use 
the system. 
The fact that we chose to incorporate coded, structured, and free text data into our 
system, makes system deployment more complicated. A typical installation of CholGate takes 
30 minutes per practice. Users have the option to change their preferences at any time or map 
new users to the system. 
Additionally, although the principles of managing patients for prevention of CVD is the 
same for both primary and secondary care setting, our system is geared to the workfl ow of 
primary care. Further research will have to show whether our system is suitable for environ-
ments outside of the primary care domain. 
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Abstract
Background: Indirect evidence show alerting users with clinical decision support systems 
(CDSS) seem to change behaviour more than requiring users to actively initiate the system. 
However, randomized trials comparing these methods in a clinical setting are lacking.
Objective: Using the CholGate CDSS we study the eff ect of alerting and on-demand decision 
support with respect to screening and treatment of dyslipidaemia.
Intervention: Alerting physicians with a CDSS or actively requiring initiation of CDSS.
Design, participants, settings and analysis: Cluster Randomized Controlled trial that included 
38 general practices in the region of Delft, the Netherlands with a total of 87851 patients. 
Practices were randomly assigned to three groups: 13 practices to use the CDSS method that 
alerted practitioners (alerting arm), 14 practices to the method requiring users to actively 
initiate the system (on-demand arm) and 11 practices to a control arm. Patients were followed 
in the practice electronic health record for at least a year from June 2004 and identifi ed as 
needing screening or treatment for dyslipidaemia. Multilevel regression methods were applied 
to account for the clustered design.
Main outcome measures: The percentage of correctly screened and correctly treated patients 
using anonymous patient record data.
Results: In the alerting group 65% of patients were screened (ORadj 5.17 95% CI[3.15-8.50]) 
compared to 35% of patients (ORadj 1.68 95%CI[1.03-2.75]) in the on-demand group, and 25% 
of patients in the control group. In the alerting group 65% of patients were treated (ORadj of 
3.75 95% CI[2.40-5.87] ) compared to 39% of patients (ORadj 1.53 95% CI[0.97-2.41]) in the on-
demand group, and 36% of patients in the control group.
Conclusion: Both the On-demand and Alerting version of CholGate improved screening 
performance for dyslipidaemia. Only CholGate Alerting signifi cantly improved treatment 
performance for dyslipidaemia by general practitioners.
Chapter 7
112
Introduction
Computerized clinical decision support systems (CDSS) are information systems that aim to 
optimize physicians’ clinical decision making1. Investigators report benefi cial eff ect of introduc-
ing CDSS in daily practice on physicians’ performance2-4. Several determinants appear to be 
critical to the successful introduction of CDSS in daily practice: providing automatic support as 
part of the clinician’s workfl ow, providing decisions at the point of care, and providing recom-
mendations rather than just assessments 5. In a recent systematic review, Garg et al studied the 
eff ect of CDSS on practitioner performance and patient outcomes2. They concluded that studies 
in which users were automatically prompted (alerted) to use the system seemed to indicate 
better performance than studies in which users were required to actively (on-demand) initiate 
the system. However, this conclusion was based on comparing the results of studies conducted 
in diff erent settings, using diff erent methods, and involved heterogeneous populations. A 
randomized controlled trial comparing the automatic alerting method with the on-demand 
method on physicians’ performance is lacking.
Cardiovascular disease (CVD) is the leading cause of mortality in industrialized countries6. 
Researchers report low primary and secondary prevention performance of physicians7-13. To 
improve both primary and secondary prevention of CVD, we developed the decision support 
system CholGate, based on recommendations for lipid management from the guidelines 
of the Dutch College of General Practitioners14-19. Taking advantage of the use of electronic 
health records (EHR) by Dutch general practitioners20, CholGate is integrated within the EHR to 
provide decision support as part of the clinician’s workfl ow. We conducted a randomized trial 
to compare the eff ect of two versions of CholGate with no CDSS, on screening and treatment of 
dyslipidaemia among general practitioners.
We hypothesize that a CDSS will improve physicians’ performance with respect to having 
no CDSS. In addition we hypothesize that the alerting method will have a better eff ect in 
increasing physician performance compared to a CDSS that requires manual activation
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Methods
CDSS Intervention         
The CholGate system is a CDSS which aids a general practitioner in the primary and secondary 
prevention of CVD with regards to lipid management. The system uses three layers of data 
available in the EHR to provide decision support: Coded data, structured data, and free text 
data. Coded data relies on widely used coding schemes to record data. In the Netherlands all 
practices use the International Classifi cation for Primary Care (ICPC) for coding diagnoses and 
the Anatomical Therapeutical Classifi cation (ATC)21 for coding medication. Structured data 
relies on locally defi ned coding schemes (that is, each individual practice has their own coding 
scheme). For each practice we identifi ed codes on the level of an individual practice used for 
specifi c conditions or measurements (e.g. constructing a local conversion table for laboratory 
measurements). Free text data consists of data recorded in free text. For each practitioner we 
relied on the physician’s recording habits, who, in busy daily practice, often use repetitive free 
text in their medical narrative22. After gathering relevant data the system identifi es two types 
of patients: those who need screening for lipid abnormalities, and secondly, those who need 
treatment for lipid abnormalities. The Dutch guidelines emphasize the need to screen specifi c, 
well-defi ned populations23. As a result, the guidelines contain detailed, sometimes complex 
descriptions of the various conditions that should lead to screening a patient24. When a patient 
is identifi ed as eligible for screening, the guidelines recommend specifi c actions. The guidelines 
distinguish between primary and secondary treatment decisions. The DCGP guidelines require 
calculation of a risk score for every patient who needs primary prevention14-19. This risk score 
is based on the Framingham risk function for CVD25. In the 1999 paper-based guidelines, the 
physician had to deduce the score from a series of tables stratifi ed by age, gender, diabetes 
mellitus, systolic blood pressure, smoking, and cholesterol/HDL cholesterol ratio. For every age 
group a threshold Framingham score exists where treatment is recommended. Researchers 
have argued that the relevant tables are complex and might be diffi  cult to use in daily prac-
tice26. In secondary prevention, the treatment decision is more straight-forward. Any patient 
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with CVD attributed to atherosclerosis and with a serum cholesterol level greater than 5mmol/l 
(193 mg/dL) should be treated with statins.
To test our hypothesis we developed two versions of the CholGate DSS; CholGate On-
demand and CholGate Alerting. Both versions analyse and interpret the patient data generating 
patient specifi c recommendations for preventative activities. An overview screen presents a 
patient’s current risk profi le to the user, as well as suggesting an action on lipid management. 
This overview is interactive: the user can enter new diagnosis, or change measurement values 
and is immediately updated. All changes are registered into the patient’s record, preventing 
duplication of tasks. This is an example of the system supporting workfl ow of the practitioner 
as far as possible, resulting in completing various workfl ow tasks as well as getting decision 
support, also. In both versions the user has access to the overview screen to see a patient’s risk 
profi le and recommendations. The only diff erence between the two versions is the alerting 
functionality.
In CholGate Alerting, the recommendations are automatically shown to the user during 
record interaction. The alert is presented in the EHR’s patient record screen. In CholGate 
On-demand a user has to actively access the recommendations of the system. 
Study population and setting       
To avoid bias by diff erent vendor systems we chose to integrate CholGate into the Elias EHR 
(ISOFT B.V.). In May and June 2004 all 56 practices in the region Delft and Westland, in the 
Netherlands, using the Elias (ISoft BV) EHR were invited to participate in the study. Only prac-
tices that fully replaced paper-based records with electronic records during patient encounters 
and who have been working in this manner for a year or more were eligible for the study. A 
total of 38 practices (80 GPs) agreed to participate in the study.
The general practice, with one or more practitioners, was chosen as unit of randomization 
because it was a defi nable entity and a logical foundation for implementing a primary care 
based intervention. In addition this prevented knowledge gained from decision support in one 
patient infl uencing the action on a possible control patient thereby underestimating the eff ect 
of the intervention27. Practices were randomly assigned into one of three arms; a control arm, 
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and two intervention arms, an on-demand arm and an alerting arm.
The CholGate CDSS was implemented by the authors at the practices that participated 
in the study. The authors confi gured the system to the local practice setting and users were 
given a tutorial on the use of the system. We installed CholGate On-demand in the on-demand 
arm and CholGate Alerting in the alerting arm. In the control arm CholGate was installed but 
all functionality was disabled for daily use. At all practices an initialization procedure was 
performed directly after installation. This procedure gathered data on the practices screening 
and treatment performance of the 360 days preceding the intervention as well as gathering the 
baseline characteristics of the patient population. As the DCGP guidelines restrict lipid manage-
ment recommendations to males between 18 and 70 years and females between 18 and 75 
years we only included these patients in our study14-19.
After initialization all data of patient record interactions, patient characteristics, and fol-
low-up data were obtained from the EHR by the system. Eligibility of patients for screening and 
treatment actions were determined from the computerized patient data (diagnoses, problems, 
prescriptions) that were available in the EHR. Eligible patients entered the study at the moment 
the patient record was opened in the GP practice during the study period. At that moment 
CholGate classifi ed the patient as needing screening or needing treatment. If a patient needed 
screening the interval in days were counted from entry until a screening action was performed 
or follow-up ended. If a patient needed treatment the interval in days were from entry counted 
until a treatment action was performed or follow-up ended. Patients who were screened 
after classifi ed as needing screening and subsequently classifi ed as needing treatment were 
included in both the screening analysis and treatment analysis. This procedure was followed in 
all arms; however, in the control arm users did not have access to the system, and did not have 
any indication that the system was active.
All patients were followed for at least one year, or until the general practice changed EHR 
vendors, that is stopped using the ELIAS system, or until the patient died. 
All patient data was anonymous. Ethical approval was waived for the study as the interven-
tion was on the practice level, and physicians were not forced to follow any suggestions.
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Outcome measures         
The primary study outcomes were the percentage of correctly screened and correctly treated1 
patients according to the DCGP guidelines’ recommendations on lipid management in relation 
to the primary and secondary prevention of CVD14-19. 
Covariates          
The cluster randomized design does not necessarily eliminate confounding due to diff erences 
in, for example, the patient mix. As covariates we considered the various patient characteristics 
(age, gender, cardiovascular disease, hypertension, diabetes mellitus, and smoking status). 
Since the follow-up time was not fi xed and infl uenced the possibility the required actions we 
considered this as a covariate as well as the number of interactions with the EHR. In addition 
we assessed the screening and treatment percentage in the year preceding the intervention to 
adjust for possible confounding.
Statistical analysis         
Logistic regression was used for comparing screening and treatment rates between interven-
tion arms; in these analyses the odds were compared between the alerting arm and the control 
arm and between the on-demand arm and the control arm while adjusting for the covariates 
that confounded the univariate association between treatment arm and outcome. Assessment 
of the confounders was based on the 10 percent change in estimate method28. For analysis 
of the screening odds the numbers of interactions with the EHR and time between being fi rst 
eligible for screening or treatment until the end of follow-up were confounders. For assessment 
of the treatment odds the number of interactions with the EHR, the time between being 
fi rst eligible for screening or treatment until the end of follow-up, existing CVD, and diabetes 
mellitus were included as confounders. To estimate the eff ect of the interventions while taking 
into account the clustered randomization we used logistic regression with the general practice 
as a random eff ect, using PROC NLMIXED in SAS. All analyses were performed with SPSS version 
1  The percentage of just screening is the number of patients eligible for screening and then screened, divided by the total number of patients 
eligible for screening. The percentage of just treatment is the number of patients eligible for treatment and then treated, divided by the total number of 
patients eligible for treatment.
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11 (Chicago, IL) and SAS Release 8.2 (version 8.2 Cary, North Carolina). 
Results
Thirty eight general practices with a total of 87851 eligible patients participated in the study, 
11 practices were randomised to the control arm, 13 to the CholGate Alerting version and 14 to 
the CholGate On-demand version (fi gure 2).  Two practices in the on-demand group were lost 
to follow up: Both practices upgraded to a better hardware solution with the vendor inadvert-
ently deleting our study data.
Practice characteristics diff ered slightly between the treatment arms, for example screen-
ing and treatment performance in the year preceding the start of the CholGate program were 
lower in the on-demand arm (Table 1). Patient characteristics were quite similar between the 
treatment arms, except for the percentage of smokers, family history of CVD, systolic blood 
pressure and the percentage of patients (table 1). For 3210 of the 87851 patients, the CholGate 
module determined that according to the DCGP guidelines screening was needed (table 2), the 
percentage was highest in the on-demand arm (39.8%) versus 34.6% in the automatic alerting 
arm and 37.8% in the control arm. The majority of patients who were identifi ed as eligible for 
screening was male, around 60 years of age, approximately 40% had CVD (mostly angina or a 
prior myocardial infarction) and 26% had diabetes (table 2).
Table 3 shows for 2953 of the 87591 patients, CholGate determined that treatment was 
needed either at becoming eligible for the study or after being screened during the study 
period (376 patients in total). A high percentage of treatment eligible persons had CVD, 
diabetes or had a Framingham risk score above 20%, which is the treatment eligibility criterium 
for primary prevention patients, between 40-50% of patients were eligible because of second-
ary prevention and the rest because of primary prevention (table 2) 
Sixty fi ve percent of screening eligible patients in the automatic alerting arm were 
screened versus 35% in the on-demand arm and 25% in the control arm (table 3). The 
automatic alerting arm had a 5 fold increased odds to be screened than patients in the control 
arm (ORadj=5.17, 95%CI: 3.15-8.50), whereas patients in the on-demand arm had a 1.68 fold 
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increased odds of being screened (ORadj=1.68, 95%CI 1.03-2.75). Of the treatment eligible 
persons 65% was treated in the automatic alerting arm, 39.7% in the on-demand arm and 
35.9% in the control arm. After adjustment for diff erences between arms the odds of treatment 
was 3.75 fold higher in the automatic alerting arm (ORadj =3.75, 95%CI 2.40-5.87) and 1.53 fold 
higher in the on-demand arm in comparison to the control arm (ORadj =1.53, 0.97-2.41). The 
automatic alerting arm had signifi cantly higher odds of being screened and treated than the 
on-demand arm (table 3). 
Discussion
This study showed that CholGate improves screening and treatment performance of dyslipidae-
mia in general practice. The CholGate Alerting version improved screening and treatment rates 
signifi cantly more than CholGate On-demand. The on-demand version improved screening of 
dyslipidaemia compared to no intervention but did not signifi cantly improve treatment rates.
Explanation of fi ndings        
The observation that the system increased physician performance in relation to dyslipidaemia 
recommendations from the guidelines can be understood when taking the workfl ow of GPs 
into account. In a busy general practice there is frequently insuffi  cient time to calculate the risk 
scores which is necessary for decisions on primary prevention according to the guidelines. The 
time needed to read and interpret paper-based guidelines might hamper physician adherence. 
As our results show, displaying recommendations from guidelines to complex decisions in a 
way that fi ts into the workfl ow of the physician, increases performance by obviating the break 
in the clinical workfl ow. 
The observation that a system that alerts a user to screening and treatment actions is 
associated with better performance than a system that requires a user to actively access recom-
mendations can be understood when taking the awareness of physician of trigger events into 
account. Primary prevention requires GPs to take various factors into account when identifying 
patients at risk. In that case a clear event that triggers the primary prevention actions is 
lacking29. However, physicians’ awareness of the need for secondary prevention activities is 
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frequently triggered by a CVD event29. The results of our study demonstrate that increasing 
awareness with alerts leads to better performance in both primary and secondary prevention.
Findings in relation to other studies
In a recent major review of 100 CDSS studies on practitioner performance and patient 
outcomes, the authors found that improved practitioner performance was associated with 
CDSS that automatically prompted (alerted) users compared with requiring users to activate 
the system2. However, none of the 100 studies under review directly studied this observation. 
Our work is the fi rst study that confi rms this association in a randomized controlled trial 
setting. Recently authors have identifi ed the critical determinants for CDSS to be successful2, 
5, 30. However, we did not evaluate the eff ect of these factors in our study, but rather kept 
them similar across the intervention groups. This means that we could measure the diff erence 
between the intended interventions (alerting and on-demand activation), without taking the 
various system eff ects listed by others into account.
The clinical implications of our fi ndings could be profound. It is known that both primary 
and secondary prevention of CVD is sub-optimally performed7-13. The eff ects of our study show 
that interventions such as CDSS can improve the primary and secondary prevention of CVD, 
and then especially if GPs are alerted to the need for action. It can be argued that an increase in 
adherence to the guidelines, as eff ected by our system, will lead to a decrease in mortality and 
morbidity due to CVD. However, further research will have to show that this is indeed the case.
Limitations
Recently authors have argued that evaluation of CDSS should focus on the eff ect on patient 
outcomes as the gold standard for evaluating CDSS2. Our study is limited by the fact that it only 
assesses the eff ect of CDSS on changing physician behaviour rather than on patient outcomes. 
However, if the CDSS is grounded on well accepted evidence based guidelines, one can argue 
that improvement in physician adherence to guidelines will result in eventual better patient 
outcomes. Further research will have to clarify whether this supposition is correct.
The performance of the CDSS depends on the way physicians capture data in their EHR. 
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Inappropriate coding of data will translate into lack of alerting or inappropriate alerting. 
Therefore, we were unable to control for patients that needed screening or treatment, but 
no data was in the record. However, we believe as benefi t from a CDSS, coding practices 
will improve. Further research will have to show what the best strategies are for helping 
appropriate coding of data.
Randomization was conducted on a practice level, and this does not deal with poten-
tial diff erences in patient characteristics between treatment arms. Through the multilevel 
logistic regression analysis we adjusted for baseline diff erences that confounded the eff ect 
estimate while taking the clustered design into account. Because of logistical reasons, the 
follow-up time diff ered between practices. Since time is an important determinant for 
screening and treatment, we adjusted for this diff erence. 
Apart from screening for all CVD risk factors, we focused on treating only one risk 
factor: lipid abnormalities. We did not perform CDSS treatment interventions on other CVD 
risk factors. Performing these extra interventions will induce exponential complexity to 
the system23, 31. Although we have been able to introduce a CDSS that eff ectively supports 
the longitudinal lipid management aspects of primary and secondary prevention of CVD, 
further research will have to show whether introducing more workfl ow patterns in the 
CDSS will have additional eff ects on physicians’ performance.
In conclusion, this study shows that both the On-demand and Alerting version of 
CholGate greatly improve screening performance for dyslipidaemia. In addition, although 
CholGate On-demand seemed to improve treatment performance, only CholGate Alerting 
signifi cantly improve treatment performance for dyslipidaemia by general practitioners.
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Figure 1 Practice randomization and study fl ow
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Table 1. Characteristics of practices participating in the study
Study arms
Alerting On-demand Control
Practice characteristics
Enrolled practices 13 12 11
Number of GPs median 2 2 2
Practice size mean (SD) 2400.5 (977.1) 2607.9 (1269.4) 2304.5 (1186.2)
Single practices mean (SD) 1695 (190) 1550 (346) 1461 (194)
Group practices mean (SD) 2841 (1019) 3137 (1233) 2787 (1257)
Record interactions mean (SD) 9 (9.1) 9 (9.3) 9 (10.1)
Screening performance % in year 
preceding intervention mean (SD) 26.1 (10.6) 22.8 (6.0) 23.7 (7.2)
Treatment performance % in year 
preceding intervention mean (SD) 33.0 (12.5) 27.1 (13.5) 34.0 (11.3)
Patient characteristics
n=31211 n=25350 n=31325
Male sex, n (%) 14065 (45.1) 14082 (45.0) 11286 (44.5)
Age Mean (SD) 43.4 (14.80) 43.2 (14.99) 43.7 (14.50)
CVD, n (%) 1182 (3.8) 1414 (4.5) 1058 (4.2)
MI, n (%) 299 (1.0) 369 (1.2) 289 (1.1)
Angina, n (%) 563 (1.8) 567 (1.8) 442 (1.7)
Tia/CVA, n (%) 269 (0.9) 328 (1.0) 257 (1.0)
PVD, n (%) 107 (0.3) 107 (0.3) 102 (0.4)
Smoking, n (%) 1188 (3.8) 1357 (4.3) 1426 (5.6)
Hypertension, n (%) 3036 (9.7) 2962 (9.5) 2312 (9.1)
Diabetes mellitus, n (%) 1115 (3.6) 1379 (4.4) 990 (3.9)
Hypertension & DM, n (%) 455 (1.5) 503 (1.6) 358 (1.4)
Family history of CVD, n (%) 285 (0.9) 278 (0.9) 445 (1.8)
Cholesterol/HDL ratio Mean (SD) 4.6 (1.38) 4.7 (1.68) 4.5 (1.40)
Cholesterol Mean (SD) 5.5 (1.04) 5.5 (1.90) 5.4 (1.52)
Glucose Mean (SD) 5.4 (1.84) 5.6 (1.84) 5.5 (1.62)
Weight Mean (SD) 81.0 (19.00) 80.6 (19.25) 78.8 (17.45)
HDL Mean (SD) 1.3 (0.40) 1.3 (0.39) 1.3 (0.39)
Height Mean (SD) 171.3 (12.38) 170.8 (34.03) 170.0 (11.06)
BMI Mean (SD) 28.8 (4.82) 28.9 (5.38) 28.4 (4.91)
Diastolic BP Mean (SD) 80.2 (9.93) 80.9 (9.90) 79.2 (10.32)
Systolic BP Mean (SD) 134.1 (19.09) 134.5 (19.57) 131.1 (19.34)
Triglycerides Mean (SD) 1.6 (1.37) 1.8 (1.44) 1.6 (1.12)
Patients on Statins, n (%) 1460 (4.7) 1420 (4.5) 1275 (5.0)
CVD: Cardiovascular disease, MI: Myocardial infarct, TIA: Transient ischaemic attack, CVA: Cerebrovascular accident, DM: Diabetes Mellitus, HDL: High density 
lipoprotein, BMI: Body mass index, BP: Blood Pressure
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Table 2 Characteristics of patients identifi ed for screening and treatment by study arm
Alerting On-demand Control
n % n % N %
Eligible for screening (percentage from 
total population) n=1079 (3.5) n=1249 (4.0) n=882 (3.5)
Age mean (SD) 59 (8.8) 59 (8.7) 58 (8.9)
Male sex, n (%) 682 (63.2) 839 (67.2) 598 (67.8)
All CVD, n (%) 402 (37.3) 501 (40.1) 370 (42.0)
MI, n (%) 129 (12.0) 164 (13.1) 129 (14.6)
Angina, n (%) 161 (14.9) 162 (13.0) 163 (18.5)
Tia/CVA, n (%) 109 (10.1) 152 (12.2) 101 (11.5)
PVD, n (%) 40 (3.7) 43 (3.4) 41 (4.6)
HT, n (%) 431 (39.9) 451 (36.1) 305 (34.6)
DM, n (%) 279 (25.9) 326 (26.1) 235 (26.6)
Family history, n (%) 12 (1.1) 23 (1.8) 21 (2.4)
Smokers, n (%) 186 (17.2) 254 (20.3) 229 (26.0)
Eligible for treatment (% from total 
population) n=1218 (3.9) n=969 (3.1) n=766 (3.0)
Patients needing treatment and 
screened during study period n (%) 201 (16.6) 94 (9.8) 72 (9.4)
Age, mean (SD) 58 (9) 59 (9) 58 (10)
Male sex, n (%) 746 (61.2) 554 (57.2) 438 (57.2)
CVD, n (%) 481 (39.5) 488 (50.4) 360 (47.0)
MI, n (%) 73 (6.0) 88 (9.1) 71 (9.3)
Angina, n (%) 238 (19.5) 222 (22.9) 155 (20.2)
Tia/CVA, n (%) 122 (10.0) 111 (11.5) 90 (11.7)
PAD, n (%) 43 (3.5) 31 (3.2) 36 (4.7)
HT, n (%) 524 (43.0) 410 (42.3) 351 (45.8)
DM, n (%) 358 (29.4) 345 (35.6) 246 (32.1)
Family history, n (%) 237 (19.5) 116 (12.0) 91 (11.9)
Smokers, n (%) 228 (18.7) 185 (19.1) 173 (22.6)
CHD risk, mean (SD) 21.3 (7.4) 23.2 (7.1) 22.6 (7.9)
Bold print signifi es statistically signifi cant diff erence with control group p<0.05
CVD: Cardiovascular disease, MI: Myocardial infarct, TIA: Transient ischaemic attack, CVA: Cerebrovascular accident, DM: Diabetes Mellitus, HDL: High 
density lipoprotein, BMI: Body mass index, BP: Blood Pressure
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Table 3 Observed screening and treatment performance by study arms and eff ect of intervention
Alerting On-demand Control
Screening
Total patients needing screening 1079 1249 882
Patients screened n (%) 701 (65.0) 438 (35.1) 225 (25.5)
Follow up time mean (SD) 316.8 (83.6) 267.9 (99.9) 284.4 (69.9)
Adjusted Odds ratio# (vs. control arm), 
95%CI 5.17 3.15-8.50 1.68 1.03-2.75 reference
Adjusted Odds ratio# (vs. on-demand arm), 
95%CI 3.06 1.73-5.39 reference
Treatment
Total patients needing treatment 1218 969 766
Patients treated n (%) 801 (65.7) 385 (39.7) 275 (35.9)
Follow up time mean (SD) 316.0 (78.6) 286.0 (92.6) 298.9 (57.1)
Adjusted Odds ratio& (vs. control arm), 
95%CI 3.75 2.40-5.87 1.53 0.97-2.41 reference
Adjusted Odds ratio& (vs. on-demand arm), 
95%CI 2.51 1.57-4.01 reference
# adjusted for time between eligibility and end of follow up, interactions with record
& adjusted for time between eligibility and end of follow up, interactions with record, CVD, Diabetes mellitus
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The aim of this research was to study the eff ect of two methods used in providing clinical 
decision support in primary care, on-demand/order entry and alerting/critiquing. Within the 
overall objective we investigated the impact of a computer-based intervention that supports 
the general practitioner in performing primary and secondary prevention of CVD. To achieve 
this objective we analyzed the practice guidelines of the Dutch College of General Practitioners 
with respect to recommendations for primary and secondary prevention of CVD, analysed cur-
rent practises of Dutch general practitioners with regards to primary and secondary prevention 
of CVD, designed the decision support system CholGate, and conducted a randomized trial to 
assess which method of decision support yields most eff ect on GP compliance to the recom-
mendations of the DCGP guidelines. Separate conclusions can be drawn from diff erent parts of 
our study, but at the same time new questions arise. We will now discuss those conclusions and 
give suggestions for future research that might give an answer on the newly raised questions.
Cross sectional analysis of guidelines      
Clinical guidelines are widely used in medicine to standardize medical treatment. Most clinical 
guidelines are published as free-text fi les, which can not be directly used for further computer 
processing. Therefore, clinical guidelines have to be translated fi rst into a machine-readable 
formal representation. To assist knowledge engineers in developing a computable version of 
narrative guidelines several tools have been developed1. Formalization of guidelines, however, 
requires consistency of guideline statements. To assess the possibility to formalize the DCGP 
guidelines on lipid management we analysed all recommendations for management of CVD 
risk factors from these guidelines on (in)consistencies. 
Our analysis showed that with respect to the management of CVD risk factors, most 
statements in the selected guidelines were consistent between the guidelines. However, we 
identifi ed eight statement inconsistencies (Chapter 2). Although the clinical relevance of the 
contradictions remains open for debate it is important to consider them from diff erent perspec-
tives. From the patient outcome perspective, the diff erence might not be large. From designing 
a CDSS’s perspective, however, the inconsistencies constitute diff erent recommendations; if 
these statements between guidelines are inconsistent, appropriate assistance through a CDSS 
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will not be possible. Clinical relevance aside, guideline adherence inadvertently suff er from 
inconsistencies; a user can be adherent to one guideline but at the same time non compliant 
to another guideline. All these factors underscore the care that guideline developing organiza-
tions must take when developing guidelines with recommendations spread across diff erent 
guidelines.
In January 2006 the DCGP published a new guideline dealing with the management of risk 
factors for CVD, both in primary and secondary prevention setting2. This guideline consolidates 
the recommendations previously distributed across various guidelines into a single guideline. 
In the new guideline the DCGP acknowledges the previous distribution of recommendations 
across diff erent guidelines and attempts to provide a better, more consolidated set of recom-
mendations. The cross consistency in statements between guidelines and the cross consistency 
in referencing to related guidelines should in our opinion be added to the checklist for guide-
line development. We believe that if our suggestions are applied to all future DCGP guidelines, 
both new and updated, developing CDSS for Dutch primary care will be easier.
Risk factor identifi cation and management      
The correct identifi cation of patients to which recommendations pertain is the starting point 
of any guideline. For the DCGP guidelines on lipid management the starting point is the 
identifi cation of patients with the four so called “conventional” risk factors (diabetes mellitus, 
hypertension, smoking, and hypercholesterolemia). 
To estimate the potential of a decision support system on lipid management we had to 
ascertain whether the identifi cation and registration of the various risk factors as suggested 
by the guidelines, is part of the daily work fl ow of general practitioners. In addition, intending 
to tightly integrate the system into the EHR - one of the success factors of a CDSS - we had to 
assess whether suffi  cient data is available for the system to process decision rules and calcula-
tions. Our study (presented in Chapter 4) shows that with respect to the risk factors for CVD, 
data regarding risk factors is identifi ed, registered and suffi  ciently available. The availability of 
the data, however, was frequently too “late”. Relating the registration of data to a CVD event, 
our research showed that the occurrence of a CVD event was the trigger for Dutch general 
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practitioners to identify and register the four conventional risk factors. This indicates that 
Dutch GPs seem to focus on the secondary prevention of CVD. In addition, relating the data to 
performance of practitioners according to the DCGP guidelines (Chapter 3), we demonstrated 
the systematic underperformance in the management of hypercholesterolemia and hyperten-
sion across the entire management process (screening, treatment, and treatment monitoring).  
A number of studies have shown that the availability of guidelines does not necessarily lead 
to the use of these guidelines by physicians. Even when authoritative guidelines are available, 
changing the behaviour of physicians has proved to be diffi  cult3, 4.
For eff ectively changing preventing behaviour of GP, the focus has to be on the awareness 
of performing preventive actions in the time frame preceding the CVD event. We realized that 
giving GP’s the tools to identify patients eligible for primary prevention, might urge them to 
perform associated measurements for CVD risk factors in the correct time frame. Therefore, 
unlike previous eff orts in decision support systems we argue that the focus should not be on 
the rules and algorithms that guide these systems - this is contained in evidence based medi-
cine itself - but rather on increasing the awareness of physicians in obtaining the relevant data. 
Giving eff ective feedback on the interpretation of data in relation to cardiovascular risk might 
lead to better case fi nding of patients.
Designing an integrated clinical decision support system   
When implementing evidence based recommendations from guidelines into a CDSS, develop-
ers have to take into account the diff erence between the static recommendations of the 
guidelines and the continuous fl ux of the evidence on which the recommendations are based.
Evidence-based medicine requires that guidelines be revised in the light of the available 
randomized clinical trials5. New trials that fi rst appear in medical journals are read by physicians, 
and may subsequently result in revision of guidelines. Adoption of recent knowledge into daily 
practice could therefore precede dissemination of revised guidelines. 
The 1999 Dutch cholesterol guideline, for example, recommended only two drugs of the 
statin class at publication: simvastatin and pravastatin. The DCGP acknowledged that other 
drugs of the statin class could have been included in their guidelines, but refrained from 
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including these drugs because of paucity on large trials on effi  ciency, eff ect and safety6. After 
1999 various articles appeared showing that other statins such as atorvastatin and cerivastatin 
have similar eff ect, effi  ciency and safety profi les7, 8. 
In Chapter 5 we showed that other statins prescribing includes 39 % of new statin prescrip-
tions. This might be an indication of GPs adopting new knowledge into daily practice. For 
successful introduction into daily practice a designer of a CDSS has to take this into account. 
Restricting prescription recommendations to the two recommended statins by the DCGP 
guideline could have hampered the successful introduction of CholGate into daily practice. 
Because our goal was to improve primary and secondary prevention of CVD by GPs, we focused 
on the treatment actions necessary to accomplish this, rather than the restrictive prescription 
recommendations of the guidelines. Prescribing a statin accomplishes this treatment action. We 
believe that this pragmatic approach enhances the successful introduction of CDSS into daily 
practice.
The fi rst step when integrating a guideline within the workfl ow of a physician is to inte-
grate the recommendations of the guideline with the data in the EHR. Implementing guidelines 
across diff erent platforms (that is, diff erent GP information systems) and across diff erent institu-
tions (that is, multiple practices) requires tailoring the system to these diff erent environments. 
Other researchers have discussed this issue; the developers of the Arden syntax, for example, 
use the term “curly brackets”9 to denote the need for defi ning local mappings from variables in 
the electronic patient record to variables known to the CDSS. In the development of CholGate, 
we distinguish three diff erent types of data that need to be extracted from the EHR and 
mapped to the CDSS: coded data, structured data and free text. Coded data are similar across 
diff erent platforms, structured data are similar for all practitioners in one setting, and free text is 
specifi c for each individual user. The consequence of such an integrating of the CDSS with the 
local environment results in tailoring the system to each environment, including each indi-
vidual user (Chapter 6). The fact that time and eff ort are required for that integration, therefore, 
is a direct consequence of the need to integrate the system to the local work fl ow. This raises 
the question of optimum balance between time and eff ort, and system functionality in CDSS. A 
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modern CDSS not only needs to provide clinical decision support, but simultaneously support 
practitioner workfl ow as well. Historically, researchers have focused on the decision making 
aspect of CDSS 10-12 However, the more various determinants for the successful implementation 
of CDSS had been identifi ed10-12, the more it became clear that workfl ow integration and sup-
port is likely to be the most important determinant for successful CDSS implementations. This 
entails that future development of CDSS have to pay attention to the workfl ow aspects of CDSS: 
as CDSS becomes more complex, so will the various workfl ow aspects. Future research will have 
to identify and analyze methodologies to support this increased complexity.
Comparing alert driven decision support with activating the system  
In Chapter 7 our results show that compared to current practice, physicians using a CDSS 
integrated into the daily workfl ow have a signifi cantly better primary and secondary prevention 
performance with respect to screening patients. In addition our results show that a CDSS alert-
ing practitioners results in better treatment performance performance than a CDSS requiring a 
user to actively access the recommendations of the system. That both methods of CDSS – alert-
ing and on-demand – resulted in better physician performance than current practice raises the 
question which method of CDSS is most appropriate for a specifi c care setting. In a busy general 
practice, making physicians aware of advisable preventive actions has clear infl uence on their 
preventive behaviour. On the other hand, CDSS only having an on-demand functionality 
demonstrated eff ect on physician behaviour as well. For example, the BloodLink system, which 
provided on-demand decision support on blood test ordering, showed clear impact on test 
ordering behaviour of Dutch GPs without using any alerting. The BloodLink success was prob-
ably a result both of eff ective workfl ow support, and delivering decision support. Integrated in 
daily practice, BloodLink relieved the physician of routines by printing a patient-specifi c blood 
order form that included the necessary patient data (such as name, age, address, etc.), the tests 
ordered and the specifi c instructions for the laboratory. BloodLink’s use of already entered 
administrative data eliminated the need for the general practitioner to re-enter these data. The 
on-demand method of BloodLink was successful as part of the diagnostic process where physi-
cians identify patients that need test ordering to prove or disprove a working hypothesis. Thus 
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the physician has already made a decision on the action (blood tests) but needs support for the 
most appropriate tests. The decision to order blood tests always precedes the need for decision 
support. Similarly to BloodLink, CholGate On-demand also required physicians to have made a 
decision on needing support prior to activating the system. BloodLink’s use of EHR data was not 
used for clinical reasoning, but only for performing administrative workfl ow support. Both the 
on-demand and alerting version of CholGate, however, while incorporating the same principles 
for workfl ow support as BloodLink, uses available EHR data for both administrative support and 
to identify the patient’s eligibility for primary or secondary prevention of CVD. 
CholGate Alerting, functioning in the background, is not part of the diagnostic proc-
ess. That is a patient visiting the GP for pulmonary complaints may at the same time have 
comorbidity like hypertension or diabetes. Based on the available EHR data, CholGate Alerting 
will identify this patient as eligible for primary prevention of CVD and alerts the physician 
Independant from the reason for encounter, CholGate initiates decision support on preventive 
activities, thus creating opportunities to perform appropriate actions during the same visit. In 
this case decision support precedes the decision of the physician on the recommended action. 
When designing a decision support system developers have to be aware of the character-
istic features of a specifi c diagnostic process in order to meet the requirements for successful 
implementation of decision support in a specifi c care process.
BloodLink provides decision support for a single occurrence (blood test ordering) in a 
care process across multiple domains (all guidelines of the DCGP) whereas CholGate provides 
decision support for multiple occurrences (e.g. blood test ordering and statin prescriptions) in a 
care process across a single domain (CVD guidelines of the DCGP). 
On-demand therefore might be the appropriate method of decision support in the case 
where physicians have already decided on an action in a care process, requiring single actions 
in multiple domains. Alerting might be the most appropriate method of decision support in 
the case where physicians are not yet aware of the need to initiate actions in a care process, 
requiring multiple actions in a single domain.
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Future directions         
We have conducted a study to assess the eff ect of two methods of CDSS in the domain of 
CVD on physician behaviour. Various authors have argued that large cluster randomized trials 
evaluating clinically relevant patient outcomes is the most appropriate way to assess the real 
eff ects of any CDSS. However, it can be argued that if physician’s behaviour is changed ac-
cording to well accepted evidence based guidelines, patient outcomes will improve. Physician 
compliance to guidelines is not the only factor that determines patient outcomes. The patient’s 
own compliance with lifestyle recommendations and medication prescriptions is the ultimate 
determinant. Therefore, even if a CDSS achieves a 100% physician compliance to guidelines, 
patient compliance will still infl uence outcomes. Finding ways in which to increase both physi-
cian compliance, and maybe more importantly, increase patient compliance becomes more 
important. As both physicians and patients are partners in the care process, involving both in 
future work on CDSS should be a focus in future research.
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Cardiovascular disease (CVD) is the leading cause of mortality in industrialized countries. 
Coronary heart disease and stroke are the principle components of CVD. Risk factors for devel-
oping CVD include smoking, male gender, diabetes mellitus, hypertension, haemostatic factors, 
family history of CVD, age, and abnormal blood lipids. Evidence exists that managing CVD risk 
factors in primary care plays an important role in decreasing the morbidity and mortality due 
to cardiovascular disease. Drug treatment for elevated cholesterol in patients with an increased 
risk for cardiovascular disease leads to a decreased morbidity and mortality. The management 
of CVD risk factors is generally referred to as primary and secondary prevention of CVD. Primary 
prevention aims to lower the incidence of the event, in other words, prevent the occurrence 
of CVD. Secondary prevention aims at reducing more and severe occurrences of CVD after the 
onset of initial CVD. The general practitioner is in a large part responsible for eff ective primary 
and secondary prevention of CVD. 
Clinical decision support systems (CDSSs) are information systems that aim to optimize 
physicians’ clinical decision making. Two methods of introducing CDSS in daily practice have 
been studied: on demand mode and alerting mode. In the on demand mode, the user decides 
when decision support is needed and then activates the CDSS. In the alerting mode, the user 
is alerted when advice is available on a patient. Although it is known that both systems are 
eff ective in providing decision support in various settings, no direct comparison of the two 
methods has been made. 
The aim of this research was to study the eff ect of two methods used in providing clinical 
decision support in primary care: on demand/order entry and alerting/critiquing. Within 
the overall objective, we investigated the impact of a computer-based intervention that 
supports the general practitioner in performing primary and secondary prevention of CVD. 
To achieve this objective we analyzed the practice guidelines of the Dutch College of General 
Practitioners (DCGP) with respect to recommendations for primary and secondary prevention 
of CVD, analysed current practises of Dutch general practitioners with regards to primary and 
secondary prevention of CVD, designed the CholGate CDSS, and conducted a randomized 
trial to assess which method of decision support yields most eff ect on GP compliance to the 
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recommendations of the DCGP guidelines.
Consistency of the guidelines       
In order to implement a guideline in a DSS, developers need to formalize the statements 
of the guideline. However, with respect to the management of chronic diseases, more than 
one guideline can be applicable. In addition patients may have more than one disease. If a 
statement in one guideline is inconsistent with a statement in another guideline the developer 
is confronted with ambiguous recommendations. In Chapter 2 we analyzed statements in the 
practice guidelines of the DCGP with respect to the management of risk factors for CVD. This 
was done to identify the possible inconsistency of statements among these guidelines which 
would be relevant when constructing a CDSS. We performed a cross sectional analysis of all 
electronically available DCGP practice guidelines dealing with CVD risk factor management 
for statement inconsistencies and reference inconsistencies. We found that six out of 74 
electronically available DCGP guidelines had either CVD or CVD risk factors as subject of the 
guideline. Eight statement inconsistencies were found and for each statement inconsistency a 
reference inconsistency was present. Given that inconsistencies were found, we recommend that 
organizations that maintain a set of guidelines update the guidelines using a cross sectional 
analysis of guidelines. Inconsistencies between guidelines might lead to physicians being 
unintentionally non-compliant with guideline recommendations. However, the inconsistencies 
were of such a nature that we could use the guidelines as a viable knowledge base to construct 
a CDSS
Identifi cation of “conventional” risk factors for CVD    
Detecting and managing the four major “conventional” risk factors – smoking, hypertension, 
diabetes mellitus, and hypercholesterolemia –  is pivotal in the primary and secondary 
prevention of CVD. To assess the preventive activities of general practitioners regarding the 
four conventional risk factors, and the associated measurements for cardiovascular risk factors 
by general practitioners in relation to the time of fi rst clinical presence of CVD, we analysed 
data in the IPCI database. IPCI is a large longitudinal general practice research database in 
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the Netherlands. In Chapter 3 we analysed anonymous data from all patients older than 18 
with newly diagnosed CVD with at least one year of history before and after fi rst clinical 
diagnosis of CVD. Details on conventional risk factors and associated measurements for the 
four cardiovascular risk factors were assessed in relation to the fi rst clinical diagnosis of CVD 
between September 1999 and August 2003. In total 157 716 patients met the inclusion criteria. 
Of the 2594 patients with newly diagnosed CVD, at least one of the four investigated risk factors 
was observed in 76% of females and 73% of males. In 40% of cases no risk factor was recorded 
before the date of fi rst CVD. In 16% of cases no associated measurements were present before 
the fi rst CVD diagnosis. We found that in daily practice general practitioners seem to focus on 
secondary prevention of CVD. Intervention strategies that aim to infl uence general practition-
ers’ case fi nding behaviour, such as the CholGate project, should focus on increasing the 
awareness of physicians in performing risk factor associated measurements in patients eligible 
for primary prevention of CVD.
Management of hypertension and hypercholesterolaemia   
The DCGP developed screening, treatment and monitoring guidelines for hypertension and 
hypercholesterolaemia to assist physicians in providing evidence based healthcare. In Chapter 
4 we report on a retrospective study to assess the management of patients with these single 
or combined conditions in Dutch general practice. This study once again used data from the 
IPCI project. Management of hypertension and hypercholesterolaemia was assessed from 
2000–2003 by measuring the numbers of patients screened for these conditions, treated 
pharmacologically, and monitored for treatment success. Approximately 11%, 3% and 10% of 
participants were eligible for screening for hypertension alone, hypercholesterolaemia alone 
and both conditions, respectively. Blood pressure screening was high in patients eligible for 
both blood pressure and cholesterol screening (>85%), whereas cholesterol screening was low 
(<56%). Among patients newly identifi ed with hypertension or hypercholesterolaemia who 
were eligible for pharmacotherapy, 29% and 43%, respectively, were not treated within one 
year of diagnosis. Undertreatment was signifi cantly lower in patients with both conditions 
(24% and 37% for antihypertensive and lipid-lowering treatment, respectively and 28% were 
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not treated for both). Among newly treated patients, in the fi rst year of treatment there was 
no record of a blood pressure or cholesterol assessment, for 35% and 72%, respectively. 
Management was sub-optimal in patients with hypertension or hypercholesterolaemia as 
well as in those with both of these conditions. The results are likely to be widely applicable, 
particularly to other European and industrialised countries that have similar free-access health 
care systems as the Netherlands. The results show that there was the possibility to improve 
physician behaviour with a CDSS such as CholGate.
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Statins and clinical endpoints       
Evidence-based medicine requires that guidelines be revised in the light of the available 
randomized clinical trials. New trials that fi rst appear in medical journals are read by physicians, 
and may subsequently result in revision of guidelines. Adoption of recent knowledge into daily 
practice could therefore precede dissemination of revised guidelines. In Chapter 5, we analyzed 
statin prescription by Dutch GP’s and compared the risk of cardiovascular and cerebrovascular 
events between atorvastatin users and other statin users in daily general practice. We per-
formed a cohort study in the IPCI database. All new statin users in the period 1 September 1999 
to 31 December 2002 were included. Multivariate Cox-regression analysis was used to compare 
the occurrence of the primary endpoint between atorvastatin users and other statin users. 
The primary endpoint was the composite outcome of fatal or non-fatal myocardial infarction, 
admission for unstable angina pectoris, fatal or non-fatal cerebrovascular accidents, or transient 
ischemic events. We identifi ed 3499 new statin users, including 797 patients with a history of 
cardiovascular disease. 1341 persons started with simvastatin (38%), 1154 with atorvastatin 
(33%), 811 with pravastatin (23%) and 193 with other statins (6%). The median follow-up 
was 1.9 years. Two hundred thirty three patients (6.7%) experienced a primary endpoint. 
Atorvastatin users had a signifi cantly lower risk of cardiovascular and cerebrovascular events 
than users of other statins (RR: 0.70, 95%CI: 0.55-0.96). The relative risks of atorvastatin users 
compared to simvastatin and pravastatin users individually were 0.70 (95%CI: 0.48-1.02) and 
0.78 (95%CI: 0.52-1.16), respectively. The protective eff ect of atorvastatin was more pronounced 
in persons without a history of CVD. Atorvastatin showed a more favourable eff ect on fatal 
and non-fatal cardiovascular and cerebrovascular events in the general population than other 
statins. Therefore, although the guidelines did not explicitly state that ‘other’ statins should be 
used in dealing with high cholesterol, we chose to incorporate other statins in the design of our 
system.
Designing the system        
After we analyzed the guidelines, analyzed current care practices, and concluded that we 
should include all statins in our system because of prevalent use, we proceeded to construct 
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CholGate (Chapter 6). Taking advantage of the use of electronic health record (EHR) by Dutch 
general practitioners, CholGate was integrated within the EHR to provide decision support 
in the clinician’s workfl ow. As researchers reported low primary and secondary prevention 
performance of physicians - they only seem to monitor and treat conditions in isolation (like 
hypertension or diabetes mellitus) without translating the measurements of single conditions 
to overall cardiovascular risk management – CholGate needed to be able to assimilate all 
data from an EHR and integrate it into the workfl ow of the GP. We constructed the underlying 
knowledge base of the system from the guidelines of the DCGP. We used various methods to 
gather relevant patient data to identify patients at risk. These methods include using structured, 
coded, and free text data. CholGate’s user interface had to fi t the EHR environment and the aim 
was to have a positive impact on physician workfl ow by, for example, automating repetitive 
task. Finally, we developed CholGate to function in both an on demand and alerting mode, 
giving us the opportunity to test both methods in a randomized trial. 
The eff ect of Alerting or On-demand decision support    
Alerting users of clinical decision support systems (CDSS) seem to change physician behaviour 
more than requiring users to actively initiate the system (on demand activation). However, 
randomized trials comparing these methods were lacking. Using CholGate we compared 
the eff ect of alerting and on demand decision support with a control group with respect to 
screening and treatment of dyslipidaemia among Dutch general practitioners. We conducted a 
Cluster Randomized Controlled trial (Chapter 7) that included 38 general practices in the region 
of Delft, the Netherlands with a total of 87851 patients. Practices were randomly assigned 
to three groups; two interventions and one control. Patients were followed in the practice 
electronic health record for at least a year from June 2004 and identifi ed as needing screening 
or treatment for dyslipidaemia. Multilevel regression methods were applied to account for the 
clustered design. Thirteen practices were assigned to use the module that alerted practitioners 
(alerting arm), 14 practices were assigned to the module requiring users to actively initiate 
the system (on demand arm) and 11 practices served as controls. The percentage of correctly 
screened and correctly treated patients using anonymous patient record data was taken as 
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main outcome measure. In the alerting group 65% of patients were screened (ORadj 5.17 95% 
CI[3.15-8.50]) compared to 35% of patients (ORadj 1.68 95%CI[1.03-2.75]) in the on demand 
group, and 25% of patients in the control group. In the alerting group 65% of patients were 
treated (ORadj of 3.75 95% CI[2.40-5.87] ) compared to 39% of patients (ORadj 1.53 95% CI[0.97-
2.41]) in the on demand group, and 36% of patients in the control group. Both the On-demand 
and Alerting version of CholGate improved screening performance for dyslipidaemia. Only 
CholGate Alerting signifi cantly improved treatment performance for dyslipidaemia by general 
practitioners. Further research will have to show whether the fi ndings can be translated to 
other settings; that is settings other than primary care, or settings including diff erent disease 
domains.
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In de geïndustrialiseerde landen zijn hartvaatziekten (HVZ) de belangrijkste doodsoorzaak. 
Hartinfarct en CVA dragen binnen de groep HVZ het meest bij aan de mortaliteit. De 
risicofactoren voor HVZ zijn: roken, mannelijk geslacht, diabetes mellitus, hypertensie, stollings-
stoornissen, voor HVZ belaste familie anamnese en afwijkend lipidenspectrum. Het in de eerste 
lijn opsporen en (medicamenteus) behandelen van deze risicofactoren is bewezen eff ectief 
voor het terugdringen van de morbiditeit en mortaliteit ten gevolge van HVZ. Deze preventieve 
maatregelen kunnen onderverdeeld worden in primaire preventie en secundaire preventie.
Het doel van primaire preventie is het optreden van HVZ te voorkomen. Met secundaire 
preventie wordt getracht om, nadat een eerste HVZ is opgetreden een tweede mogelijke 
ernstiger verlopend HVZ te voorkomen. Primaire en secundaire preventie is een belangrijke 
taak voor de huisarts.
Beslissingsondersteunde systemen zijn informatie systemen die gericht zijn op het 
ondersteunen en optimaliseren van het besluitvormingsproces van een arts.
Twee methoden van invoeren van beslissingsondersteunde systemen in de dagelijkse 
praktijk zijn uitgebreid bestudeerd: de methode die gebaseerd is op de behoefte van de 
gebruiker aan beslissingsondersteuning en de methode waarbij het systeem de gebruiker er op 
attendeert dat voor een specifi eke patiënt beslissingsondersteuning beschikbaar is. Daar waar 
de eff ectiviteit van beide methoden afzonderlijk wetenschappelijk werd vastgesteld, ontbreekt 
tot nu toe een vergelijking van beide methoden met elkaar. In onze studie vergelijken wij 
het eff ect van beide methoden van beslissingsondersteuning op de primaire en secundaire 
preventie in de huisartsenpraktijk 
Daartoe onderzochten wij eerst the standaarden van het Nederlands Huisartsen 
Genootschap (NHG) op aanbevelingen voor primaire en secundaire preventie van HVZ. 
Vervolgens bestudeerden wij hoe op dit moment in de huisartsenpraktijk primaire en secun-
daire preventie wordt toegepast. Daarna ontwierpen wij de beslissingsondersteunende module 
CholGate en voerden ten slotte een gerandomiseerde klinische studie uit om vast te stellen 
welke methode van beslissingsondersteuning het meeste eff ect heeft op het zich houden aan 
de NHG-standaarden door de huisartsen.
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Consistentie van de NHG-standaarden      
Voor de implementatie van standaarden in een beslissingsondersteunende module dienen de 
aanbevelingen uit de standaard eerst geformaliseerd te worden. In het geval van chronische 
ziekten kan het zijn dat meer dan één standaard van toepassing is. Bovendien kunnen patiën-
ten meer dan één ziekte hebben. Als een aanbeveling uit de ene standaard niet overeenstemt 
met een vergelijkbare aanbeveling uit een andere standaard, dan wordt de ontwikkelaar van 
beslissingsondersteunende module geconfronteerd met ambiguïteit in de aanbevelingen. In 
Hoofdstuk 2 Vergeleken wij alle NHG-standaarden op aanbevelingen voor risicomanagement 
van HVZ met als doel eventueel bestaande inconsistenties tussen de standaarden op het spoor 
te komen. Door middel van een cross sectionele analyse onderzochten wij alle elektronisch 
beschikbare NHG-standaarden, die HVZ risicomanagement als onderwerp hadden, op 
inconsistentie in aanbevelingen en literatuur referenties. Van de 74 elektronisch beschikbare 
NHG-standaarden bleken zes standaarden HVZ of risicofactoren voor HVZ als onderwerp te 
hebben. In deze standaarden stelden wij 8 inconsistente aanbevelingen vast. Tussen elk van die 
inconsistente aanbevelingen was ook sprake van inconsistentie in de literatuur referenties. Voor 
organisaties die richtlijnen uitgeven en onderhouden is het aanbevelenswaardig om vooraf-
gaand aan de uitgave van een nieuwe richtlijn danwel de update van een al bestaande richtlijn 
een, als door ons beschreven, cross sectionele analyse van de in beheer zijnde richtlijnen uit te 
voeren. Immers inconsistentie tussen richtlijnen kan aanleiding geven tot ongewild afwijken 
van de aanbevelingen uit die richtlijnen door artsen. Gezien de beperkte hoeveelheid gevon-
den inconsistenties konden wij de richtlijnen gebruiken als kennisbank bij de ontwikkeling van 
CholGate. 
Identifi catie van de “conventionele” risicofactoren voor hartvaatziekten  
Het opsporen van de vier belangrijkste “conventionele” risicofactoren – roken, hypertensie, 
diabetes mellitus en hypercholesterolemie - staat centraal bij primaire en secundaire preventie. 
Om een indruk te krijgen van de mate waarin huisartsen het risicoprofi el van hun patiënten 
in de dagelijkse praktijk vaststellen in relatie tot een eerste episode van HVZ, analyseerden wij 
gegevens uit de IPCI database, een grote onderzoeksdatabase gevuld met door huisartsen 
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geleverde patiënt gegevens. In Hoofdstuk 3 beschrijven wij onze analyse van geanonimiseerde 
gegevens van patiënten 18 jaar en ouder met een eerste episode van HVZ, van wie minimaal 
een jaar voorafgaand en een jaar na het begin van deze episode gegevens beschikbaar waren. 
Voor de periode september 1999 tot augustus 2003 stelden wij voor deze patiënten vast of en 
in welke mate het risicoprofi el vóór en na het begin van de episode van HVZ aanwezig was in 
het patiënten dossier. In totaal voldeden 157.716 patiënten aan de inclusiecriteria. Van de 2495 
patiënten bij wie een eerste episode van HVZ werd vastgesteld was bij 76% van de vrouwen en 
bij 73% van de mannen minstens een van de risicofactoren aanwezig in het dossier. In 40% van 
de gevallen was geen enkele risicofactor vastgelegd voorafgaand aan de eerste HVZ episode . 
In 16% van de gevallen was geen risicoprofi el bekend voorafgaand aan de eerste HVZ episode. 
Wij stelden vast dat in de huisartsenpraktijk het accent vooral ligt op secundaire preventie van 
HVZ. Dit betekent dat projecten, zoals het CholGate project die bedoeld zijn om gedragsveran-
dering van huisartsen te bewerkstelligen zich vooral zullen moeten richten op het zich bewust 
worden van huisartsen van de noodzaak van het vaststellen van het risicoprofi el bij patiënten 
die in aanmerking komen voor primaire preventie.
Management van hypertensie and hypercholesterolemie   
De door het NHG ontwikkelde hypertensie en hypercholesterolemie standaarden geven 
huisarts houvast bij het screenen, vervolgen en behandelen van specifi eke doelgroepen en het 
leveren van evidence based gezondheidszorg 
In Hoofdstuk 4 laten wij de resultaten zien van een retrospectieve studie in de huisartsen-
praktijk naar de manier waarop Nederlandse huisartsen in de dagelijkse praktijk omgaan met 
de begeleiding en behandeling van patiënten met hypertensie en/of hypercholesterolemie. 
Ook deze studie maakte gebruik van data uit het IPCI project. Wij gingen voor de periode 2000-
2003 de mate van opsporen, behandelen en begeleiden van patiënten met hypertensie en hy-
percholesterolemie na door telling van het aantal patiënten dat gescreend was op hypertensie 
en hypercholesterolemie, door telling van het aantal medicamenteus behandelde patiënten en 
door telling van het aantal patiënten bij wie het resultaat van de behandeling door de huisarts 
was vastgesteld. Voor alleen hypertensie screening kwam 11% van de onderzochte populatie in 
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aanmerking. Voor hypercholesterolemie kwam 3% en voor zowel hypertensie als hypercholes-
terolemie kwam 11% van de onderzochte populatie in aanmerking voor screening. In de groep 
die in aanmerking kwam voor zowel hypertensie als hypercholesterolemie screening bleek in 
meer dan 85% de bloeddruk gemeten en in minder dan 56% het cholesterol bepaald. Van de 
nieuw geïdentifi ceerde patiënten met hypertensie en hypercholesterolemie die in aanmerking 
kwamen voor medicamenteuze behandeling werd respectievelijk 29% en 43% tot één jaar na 
de diagnose nog niet behandeld.
Onderbehandeling kwam signifi cant minder voor bij patiënten die zowel hypertensie als 
hypercholesterolemie hadden (24% geen behandeling voor hypertensie, 37% geen behande-
ling tegen te hoog cholesterol en 28% geen behandeling voor zowel hoge bloeddruk als hoog 
cholesterol). Van de nieuw behandelde patiënten was in 35% van de gevallen geen uitslag van 
een bloeddrukmeting en in 72% van de gevallen geen uitslag van een cholesterol bepaling 
in het dossier aanwezig gedurende het eerste jaar van de behandeling. De resultaten van ons 
onderzoek laten zien dat in Nederland sprake is van een suboptimale begeleiding van patiënt-
en met hypertensie en hypercholesterolemie. Het lijkt aannemelijk dat voor andere Europese 
en geïndustrialiseerde landen met vergelijkbare vrije toegang tot de gezondheidszorg de 
resultaten niet veel beter zullen zijn. Met behulp van beslissingsondersteunende systemen als 
CholGate zou mogelijk een meer optimale begeleiding van deze patiëntencategorie bereikt 
kunnen worden.
Statines en klinische eindpunten       
Evidence based geneeskunde vereist een continue herziening van richtlijnen in relatie tot de re-
sultaten van gepubliceerde gerandomiseerde onderzoeken. Echter voordat herziene richtlijnen 
uitgebracht worden kunnen artsen de onderzoeken, waarop de herzieningen van de richtlijn 
gebaseerd zijn, al gelezen hebben in de wetenschappelijke medische tijdschriften. Dit kan tot 
gevolg hebben dat recente inzichten al toegepast wordt in de dagelijkse praktijk nog voordat 
de herziene richtlijn is gepubliceerd. In Hoofdstuk 5, onderzoeken wij het voorschrijfgedrag van 
Nederlandse huisartsen voor wat betreft statines en vergelijken de kans op hartvaatziekten 
tussen gebruikers van atorvastatine en andere statines in de dagelijkse praktijk. Wij voerden 
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daartoe een cohort studie uit in de IPCI database. Wij includeerden alle nieuwe gebruikers van 
statines in de periode 1 september 1999 tot 31 december 2002. Om het optreden van klinische 
eindpunten te vergelijken tussen gebruikers van atorvastatine en gebruikers van andere 
statines pasten wij de multivariabel Cox-regressie analyse toe. Het primaire eindpunt was 
het opgetelde resultaat van het aantal fatale of niet fatale hartinfarcten, ziekenhuisopnames 
vanwege instabiele angina pectoris, aantal fatale of niet fatale CVA of aantal TIA’s. Wij identi-
fi ceerden 3499 nieuwe statine gebruikers, van wie 797 met HVZ in de voorgeschiedenis. Van 
de 3499 nieuwe gebruikers kregen 1341 patiënten simvastatine (38%) voorgeschreven, 1154 
atorvastatine (33%), 811 pravastatine (23%) en 193 een van de andere statines. De mediane 
follow up was 1,9 jaar. Twee honderd drieëndertig (6,7%) patiënten kregen te maken met een 
primair eindpunt
Patiënten die atorvastatine slikten hadden een signifi cant lager risico op HVZ dan patiën-
ten die een van de andere statines slikten (RR: 0.70, 95%CI: 0.55-0.96). Het relatieve risico van 
atorvastatine slikkers was 0.70 (95%CI: 0.48-1.02) vergeleken met simvastatine en 0.78 (95%CI: 
0.52-1.16) vergeleken met pravastatine. Het beschermende eff ect van atorvastatine kwam het 
duidelijkst tot uiting bij patiënten zonder HVZ in de voorgeschiedenis. Atorvastatine had een 
beter beschermend eff ect op fatale en niet fatale hartvaatziekten in de algemene populatie dan 
de andere statines. 
Hoewel in de NHG-standaarden atorvastatine niet genoemd wordt als voorkeurmedicatie 
bij de behandeling van hypercholesterolemie hebben wij, op grond van deze bevindingen, 
ervoor gekozen om behalve simvastatine – het voorkeurmedicijn in de NHG-standaard - ook de 
mogelijkheid van het voorschrijven van andere statines op te nemen in CholGate.
Het ontwerpen van CholGate       
Uitgaande van onze bevindingen uit onze analyse van de NHG-standaarden en onze bevin-
dingen uit onze retrospectieve studie in de huisartsenpraktijk ontwikkelden wij de module 
CholGate (Hoofdstuk 6). Het feit dat Nederlandse huisartsen algemeen gebruik maken van een 
huisartsen informatie systeem (HIS) stelde ons in staat CholGate in het HIS te integreren en op 
die manier beslissingsondersteuning aan te bieden ingebed in de dagelijkse praktijkvoering. 
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Omdat uit onderzoek was gebleken dat artsen beperkt uitvoer geven aan primaire en secun-
daire preventie van HVZ - risicofactoren als hypertensie en diabetes mellitus worden afzon-
derlijk vastgelegd en behandeld zonder dat de vertaalslag plaatsvindt naar het vastleggen en 
aanpakken van het complete cardiovasculaire risicoprofi el- moest CholGate in staat zijn om 
alle in het HIS aanwezige gegevens beschikbaar te maken voor HVZ risico-inventarisatie tijdens 
de dagelijkse praktijkvoering. Voor de onderliggende kennisbank van CholGate gebruikten 
wij de relevante NHG-standaarden. Voor het verkrijgen van relevante patiëntgegevens uit het 
HIS pasten wij verschillende methoden toe om gebruik te kunnen maken van gestructureerde, 
gecodeerde en vrije tekst gegevens. Het gebruikers interface van CholGate moest aansluiten 
bij de interface van het gebruikte HIS. Het doel van CholGate was een positieve bijdrage 
leveren aan de dagelijkse praktijkvoering van huisartsen, bijvoorbeeld door het automatiseren 
van herhaald voorkomende taken. Om de methode die gebaseerd is op de behoefte van de 
gebruiker aan beslissingsondersteuning en de methode waarbij het systeem de gebruiker er 
op attendeert dat er voor een specifi eke patiënt beslissingsondersteuning beschikbaar is in een 
gerandomiseerd onderzoek met elkaar te kunnen vergelijken, zorgden wij ervoor dat beide 
methoden door CholGate toegepast konden worden. 
Het eff ect van beslissingsondersteuning volgens de methode “behoefte 
gebruiker” en de methode “attenderen gebruiker”     
Systemen die gebruikers attenderen op beschikbaarheid van beslissingsondersteuning lijken 
meer invloed te hebben op gedragsverandering van artsen dan systemen die gebaseerd zijn op 
de behoefte van de gebruikers aan beslissingsondersteuning. Gerandomiseerd onderzoek dat 
beide methoden vergelijkt ontbreekt tot nu toe. Door middel van een cluster gerandomiseerd 
onderzoek (Hoofdstuk 7) vergeleken wij het eff ect van beide methoden op het screenen en 
behandelen van hypercholesterolemie door huisartsen die gebruik maakten van CholGate met 
een controle groep. Dit onderzoek omvatte 38 huisartsenpraktijken in de regio Delft, met in 
totaal 87851 patiënten. De praktijken werden gerandomiseerd in 3 groepen: twee interventie 
groepen en 1 controle groep. Vanaf juni 2004 werden patiënten gedurende tenminste 1 jaar 
gevolgd en in die periode werd vastgesteld of bij hen sprake was van een indicatie voor scree-
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ning en behandeling van hypercholesterolemie. Vanwege het clusteren in de opzet van ons 
onderzoek pasten wij multilevel regressie analyse. Dertien praktijken werden gerandomiseerd 
in de “attenderen gebruiker” arm, 14 praktijken in de “behoefte gebruiker” arm van het onder-
zoek en 11 praktijken in de controle groep. Als primaire uitkomstmaat kozen wij het percentage 
correct gescreende en correct behandelde patiënten op basis van geanonimiseerde patiënten 
data. In de “attenderen gebruiker” groep werd 65% van de patiënten gescreend (ORadj 5.17 
95% CI[3.15-8.50]) vergeleken met 35% van de patiënten in de “behoefte gebruiker” groep 
(ORadj 1.68 95%CI[1.03-2.75]) and 25% van de patiënten in de controle groep. In de “attenderen 
gebruiker” groep werd 65% van de patiënten behandeld (ORadj of 3.75 95% CI[2.40-5.87] ) 
vergeleken met 39% van de patiënten (ORadj 1.53 95% CI[0.97-2.41]) in de “behoefte gebruiker” 
groep (ORadj 1.68 95%CI[1.03-2.75]) and 36% van de patiënten in de controle groep. Zowel in 
de “attenderen gebruiker” als in de “behoefte gebruiker” groep gaf CholGate aanleiding tot 
een statistisch signifi cant betere screening op hypercholesterolemie. Een statistisch signifi cant 
betere behandeling trad alleen op in de “attenderen gebruiker” groep. Verder onderzoek moet 
uitwijzen of onze bevindingen ook van toepassing zijn in een andere setting dan de eerste 
lijnssetting en voor andere ziektedomeinen dan HVZ.
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